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The vast diversity of HIV-1 infections has greatly impeded the development of a 
successful HIV-1/AIDS vaccine.  Previous vaccine work has demonstrated limited levels of 
protection against SHIV/SIV infection, but protection was only observed when the challenge 
virus was directly matched to the vaccine strain.  As it is likely impossible to directly match the 
vaccine strain to all infecting strains in nature, it is necessary to develop an HIV-1 vaccine that 
can protect against a heterologous viral challenge.  Envelope-based vaccines were developed 
containing gp120 monomers, gp140 trimers and gp160 on the surface of a virus-like particle.  
Vaccination studies indicated that similar systemic levels of Env-specific antibodies were 
generated by each vaccine.  However the VLP-based vaccine led to increased recognition of Env 
epitopes as well as a significant increase in mucosal Env antibody responses.  Also the VLP-
based vaccine led to the development of strong cellular responses to both Env and Gag.  
Therefore the VLP platform was moved forward to develop broadly reactive vaccines.  
Consensus and Polyvalent clade B and clade C vaccines were developed and investigated for 
cellular responses in mice.  The results indicated that both Polyvalent and Consensus VLP 
vaccines led to an increase in the number of cellular Env epitopes recognized as compared with 
primary Envelope-based vaccines.  These findings were true for both clade B and clade C 
vaccines.  To determine the level of protection generated by VLP based vaccines, consensus 
clade B as well as a polyvalent clade B vaccine were investigated in non-human primates.  The 
polyvalent clade B vaccine led to the protection of 3 out of 4 challenged animals with decreased 
viral burden observed in the infected individual.  Overall these studies indicate that a virus-like 
particle vaccine encoding multiple primary envelopes is a promising HIV-1/AIDS vaccine 
strategy for protecting against heterologous HIV-1 viruses.      
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1.1 FOREWORD 
Additional information about the immunological immune responses associated with HIV-1 
infection and protection as well as further information about HIV-1 envelope was added to the 
previously published review for completeness.  A new discussion of the HIV-1 vaccine trial in 
Thailand was also added.     
1.2 INTRODUCTION 
In July, 2008, there were 33.2 million people infected with the human immunodeficiency virus 
(HIV) with ~2.5 million being new infections [1].  Throughout the world, individuals are 
infected with a diverse range of HIV isolates [1].  While diversity is an issue with many HIV 
gene products, the greatest amount of diversity is found in the envelope (Env) glycoprotein.  The 
Env amino acid sequences can differ by as much as 15% between isolates within a single clade 
and greater than 35% between envelopes from different clades.  This diversity is one of the 
major obstacles facing the development of AIDS vaccines.  Therefore, an effective AIDS 
vaccine must overcome the challenges associated with HIV sequence diversity.   
The development of
 
a successful HIV/AIDS vaccine continues to be high-priority for 
researchers. There have been many failures from the first clinical trials using Env-only based 
vaccines to the more recent
 
Vaxgen trial (Reviewed in[2-3]).  These vaccines
 
failed to induce 
neutralizing antibody responses. Due to the genetic
 
variability of the viral envelope proteins or 
the display of epitopes in the proper three-dimensional structure, the
 
virus can escape elicited 
neutralizing antibodies.  In addition, there are difficulties
 
in identifying immunogens and 
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immunization platforms that consistently
 
induce antibodies that can neutralize isolates from 
different clades.
  
In light of the difficulties in eliciting neutralizing antibodies,
 
the field switched 
its focus away from vaccines that induce
 
humoral immunity toward immune responses
 
that 
reduce viral load and transmission [4-5].  This shift was prompted by data showing
 
that T cell–
mediated immunity was critical for resistance
 
to lentiviral infection.  However, the recent failure 
of the candidate vaccine from Merck, which was the first vaccine designed
 
to elicit strong 
cellular immunity, was a tremendous setback for AIDS vaccine researchers.  This Ad5-based 
vaccine showed no protection against
 
infection and even more significant, the vaccine appeared 
to increase
 
the rate of HIV infection in individuals with prior immunity
 
against the adenovirus 
vector. Even though this vaccine elicited HIV-specific immunogenicity
 
in earlier studies, there 
were limited multifunctional responses. 
Therefore, there is a new emphasis towards more basic scientific discovery to overcome 
the underlying obstacles that hinder the design of an effective prophylactic HIV vaccine.   The 
ultimate goal is to enhance a preventive vaccine that could interrupt HIV transmission and/or 
substantially control disease progression.  This re-focused effort is addressing some 
fundamental issues associated with HIV infection and transmission to improve the basic 
understanding of the immune system’s response to natural infection and vaccination, to dissect 
the mechanisms of protection, and to use this knowledge to identify and design effective 
immunogens and approaches toward manipulating the immune response for an improved 
vaccine. The use of appropriate animal models for understanding the pathogenesis and 
transmission of lentiviruses is necessary to construct effective HIV vaccine immunogens.  
There are many challenges for AIDS vaccine researchers including the development of 
delivery mechanisms to elicit robust B cell and T cell immunity in appropriate immune 
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compartments, the use of appropriate animal models to understand the correlates of protection, 
and vaccine assays to assess the induction of immunity. 
1.3 HIV-1 DIVERSITY IN AIDS VACCINE DEVELOPMENT 
HIV-1 is a member of the family Retroviridae and the genus Lentiviridae [6].  The HIV-1 RNA 
genome encodes the essential retrovirus genes gag, pol, and env, as well as the additional 
accessory/regulatory genes vif, vpr, vpu, rev, tat, and nef (Fig. 1) (reviewed in [6]).  Envelope, 
located on the surface of viral particles, mediates binding to cellular receptors and entry into 
cells.  The uncleaved envelope protein (Envgp160) is a highly glycosylated molecule that helps 
mask it from the immune system.  Envgp160 is cleaved into Envgp120 and Envgp41 [7].  On the 
surface of the virion, envelope forms trimers with Envgp120 on the outer surface bound to Envgp41 
spanning the cellular membrane [8].  Envgp120 is composed of the constant regions C1-C5 and the 
variable regions V1 to V5 (Fig. 2).   
A central feature of lentiviruses in general, and HIV-1 in particular, is the propensity for 
these viruses to rapidly mutate and evolve in response to immunological or other selective 
pressures.  While all of the viral genes are susceptible to mutation and protein variation, the 
envelope proteins are hotspots of sequence variation, as they are primary targets for host immune 
responses, and Env has evolved to permit substantial sequence variability to confound immune 
recognition and control.  Thus, HIV-1 populations at the individual and global levels exist as a 
heterogeneous mixture of genomic quasispecies unique to a patient or on a larger scale to a 
geographical area.  With all of this diversity, it is reasonable to ask whether there is any 
commonality that can be identified and targeted for vaccine development among diverse HIV-1 
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envelope species.  Based on viral genetic distances and positions in phylogenetic trees, HIV-1 
has been divided into three groups:  M, O, and N (Fig. 3). Group M viruses are found globally 
and largely responsible for the AIDS pandemic, while groups O and N viruses are restricted to 
west central Africa. Viral envelope sequences differ by up to 50% between these groups.  Within 
group M, HIV-1 isolates have been further divided into distinct clades (designated A-K) that 
differ in envelope sequence by as much as 35% [9].  Envelope sequences can also differ by up to 
15% between viruses in the same clade.  There are also circulating recombinant forms (CRFs).  
CRFs are viral isolates that are the combination of two or more viral isolates from different 
clades that have been found in at least three epidemiologically independent individuals [10].  The 
combination of the high diversity and isolates within clades and between clades indicates that a 
vaccine based on a single isolate is unlikely to provide protection against all possible exposures 
to HIV-1 isolates.  This point is further emphasized by studies that show protection can be 
elicited by vaccines against homologous challenge viruses, but not against heterologous 
challenges [11-13].  
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Figure 1 Genomic organization of the HIV-1 proviral genome.  
Structural and enzymatic proteins are encoded by the gag, pol, and env genes.  Regulatory gene 
products are encoded by the tat and rev genes and the major accessory proteins are encoded by 
the vif, vpu, vpr, and nef.  The long terminal repeats (LTR) are sites for initiation of viral RNA 
synthesis and necessary for proviral integration into host cell chromosomes.   
 
 
Figure 2 Schematic of HIV-1 envelope. 
 (A.) shows the division of Envgp160 into gp120 and gp41 as well as the regions of Envelope and 
their location within gp120 and gp41.  (B.) A Schematic of folded gp120.  The constant regions 
are shown in black with the variable regions shown in red.  Disulfide bonds are shown in green.  
Structure was determined by Leonard et al[14].      
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Figure 3 HIV-1 Nomenclature. 
HIV-1 is divided into three Groups: Main (M), Outlier (O) and Non-M/Non-O (N).  Groups M, 
O, and N are shown as large ovals.  Group M is further divided into clades which are shown as 
small ovals arrows pointing from the Group M oval.  Clades A and F have also been further 
divided into A1/A2 and F1/F2.  
1.4 HIV ENVELOPE 
Envelope is necessary for receptor binding and viral entry [15-18].  The env gene is 
expressed as a polyprotein precursor, Envgp160.  Envgp160 is then cleaved by a cellular protease, 
furin, into the two Env glycoproteins, gp120 and gp41which associate through noncovalent 
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interaction.  These molecules form a multimeric structure (most likely a trimer) on the surface of 
the virion [19-22].  Envgp41 forms the transmembrane domain of the Env complex, while Envgp120 
is presented on the surface of infected cells or virions.    Upon infection, Envgp120 binds to human 
CD4 (hCD4) on the surface of target cells [23-26].  This interaction results in a conformational 
change in Envgp120, which exposes the chemokine receptor-binding domain.  Binding of the virus 
to the chemokine receptor (CCR5 or CXCR4) leads to another conformational change in Envgp120 
that exposes the fusogenic domain in Envgp41.  The fusogenic domain instigates entry of the viral 
core by fusing the viral and host cell membranes [23, 27-28]. 
1.5 CHEMOKINE CO-RECEPTOR USAGE 
The binding of the chemokine co-receptor is a necessary step in viral infection as stated above.  
However, different HIV-1 isolates utilize different chemokine receptors for viral entry.  Sexually 
transmitted viruses and virus isolated early after infection primarily utilize the CCR5 
receptor[29].  As the disease progresses, there is an expansion in receptor utilization.  Viral 
isolates found years after the initial infection or during late-stage disease, predominately initiate 
infection through the binding to CXCR4[29].   
1.6 HIV-1 INFECTION 
There are four major modes of HIV-1 transmission:  1) sexual intercourse, 2) blood 
products, 3) contaminated needles and 4) mother-to-child during the prenatal period 
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[30].   After infection the time until disease progression can vary greatly between 
individuals.  In general, the first symptoms of clinical AIDS become evident 8-15 years 
after infection.   
 HIV Infection has three distinct phases.  The first phase is an acute infection 
which is marked be rapid replication of virus followed by a steady decline in virus 
levels.  This phase is often accompanied by flu-like symptoms which go unrecognized 
as being caused by HIV-1 infection.  During this phase the activation of cytotoxic T cells 
(CTL) and induction of anti-HIV antibodies result in containment of the initial virus.  
An increase in CD8+ cytotoxic T lymphocytes is also often seen, but neutralizing 
antibodies are not detected until 6 months after infection.  CD4+ T lymphocytes decrease 
during this phase but return to near normal levels after six months. 
The second phase of HIV-1 is characterized by low levels of detectable virus and 
maintained CD4 counts.  The level of detectable virus (set-point) is often prognostic of 
the disease course.  High set-points are associated with rapid disease progression while 
low set-points to undetectable virus are associated with slow to non-progression of 
disease [31-33].  During this phase most infected individuals remain asymptomatic.   
The final phase of disease is characterized by a sharp increase in viral load as 
well as decreasing CD4 lymphocyte levels and is most associated with AIDS.  AIDS is 
characterized by a state of immunodeficiency that allows for the development of 
secondary, opportunistic infections.  Some of the most prevalent opportunistic 
infections are Pneumocystis carinii, Cryptosporidium, Toxoplasma, Mycobacterium 
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avium/tuberculosis and Salmonella [34-39].  Tumors are also usually found in AIDS 
patients some of the most common are Kaposi’s sarcoma, non-Hodgkin’s lymphoma 
and primary lymphoma of the brain [40-43].   
1.7 VACCINE APPROACHES TO AIDS. 
The ultimate goal of an AIDS vaccine is to elicit potent cellular and humoral immune responses 
that will result in enduring, broadly protective immunity.  While much effort has focused on 
elucidating the mechanisms and specificity of cellular immune responses, less is known about 
virus-specific antibody responses.  It has been well established that cellular immune responses 
mediate viral control during the primary infection and antibody depletion studies in the 
SIV/monkey model also demonstrated a role for cellular immunity in maintaining the viral set-
point in chronic infection [44].  On the other hand, passive protection experiments using human 
monoclonal antibodies resulted in protection against virus exposure in the HIV-1/chimp [45-46], 
SIV/monkey [47-50] and SHIV/monkey models [51-57], demonstrating the ability of antibody 
alone to mediate protection against pathogenic virus infection.  Thus, the goal of an effective 
AIDS vaccine should be to elicit as robust and broadly reactive cellular and humoral immunity 
as possible, thereby maximizing the potential for protection from variant HIV-1 strains by 
different routes of exposure.   
Initial trials using monomeric envelope proteins elicited high titer antibody responses 
against the immunogen [58-65].  However, while these single envelope vaccines have proven 
protective in both SIV and HIV non-human primate challenge models, protection was only 
observed when the envelope in the vaccine was precisely matched to the envelope on the 
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challenge virus [11-13].  These results suggest that envelope diversity is an important obstacle in 
the development of an effective AIDS vaccine.  This is supported by the fact that single envelope 
vaccines have not been successful in humans, most likely due to the inability to pre-select the 
challenge virus in humans and the tremendous diversity of HIV-1 isolates. 
Recent vaccine studies using a polyvalent Env vaccine elicited broader immune 
responses, particularly neutralizing antibodies, but did not provide sterilizing protection against 
heterologous SHIV infection in pigtailed macaques [66].  Interestingly, animals in the 
multivalent vaccine group, but not those immunized with the monovalent vaccine, exhibited 
markedly lower levels of plasma virus than monkeys in the control group, suggesting superior 
cell-mediated responses induced by the polyvalent vaccine [66].  Therefore, it appears that 
immune responses capable of recognizing conserved epitopes within Env, with the concomitant 
ability to recognize these epitopes on more than one strain of HIV-1, may play an important role 
in inhibiting the viral spread in vivo.  In addition to Env stimulating classical cellular and 
neutralizing antibody responses, due to the surface exposure of Env on both virions and infected 
cells, antibodies can also support complement-mediated lysis of virions and antibody dependant 
cellular cytotoxicity (ADCC) of infected cells.  Despite a lack of reliable correlates for immune 
protection against HIV-1 infection, an effective vaccine against HIV or AIDS will most likely 
need to elicit high levels of cross-reactive neutralizing antibodies in combination with a robust 
cell-mediated response against multiple viral antigens.  Toward this end, researchers have 
demonstrated a critical correlation of the maturation of immune responses to SIV, SHIV, and 
other lentivirus envelope proteins and the development of protective immunity in animals 
inoculated with live attenuated vaccine strains [50, 67-73].  Thus, an effective AIDS vaccine 
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may need to include a full-length, native envelope protein to enhance the breadth and maturation 
of both cellular and humoral immune responses. 
Neutralizing antibodies, CD4
+
 and CD8
+
 T-cell responses, and innate immunity have all 
been linked to protective efficacy.  However, none of these immune parameters are universal.  
Vaccine studies performed in non-human primates (NHP) indicate that protection from infection 
may be possible in humans [74-77].  Passively transferred neutralizing antibodies can protect 
against infection, but neutralizing antibodies have been difficult to elicit by vaccination.  Live-
attenuated SIV vaccines are able to protect NHP against subsequent infection [78-80].  Due to 
the possibility of reversion, live-attenuated HIV-1 vaccines are not suitable for human use.  
However these types of vaccines do offer an effective mechanism for studying correlates of 
protection.  Results from live-attenuated SIV infection studies indicate that cellular and humoral 
immunity elicited at the site of challenge can offer some level of protection from disease [78-80].  
However, these responses were only protective when the challenge virus was homologous to the 
vaccine.  These monkeys were not protected against heterologous challenge viruses indicating 
that these vaccines elicited a restricted breadth of immunity [66, 81-82].  Due to the vast 
diversity of HIV-1 isolates circulating in the population, it is unlikely that a vaccine based on a 
single viral isolate will be able to protect against human infection.  
1.8 CENTRALIZED SEQUENCES 
Centralized sequences are designed to limit the genetic distance between any given viral isolate 
and the vaccine strain.  Vaccines using this approach can be designed against any protein.  Three 
primary methods have been used to design centralized vaccines for HIV (Fig. 4).  Each method 
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utilizes a given population of sequences that are based on a diverse set of parameters, such as the 
regional location of viral isolation, the HIV clade, the year of isolation, or the specific co-
receptor usage.  A phylogenic tree is then developed using primary viral protein sequences to 
develop one of two types of centralized sequences: center-of-the-tree or ancestral.  Center-of-the-
tree sequences are based upon generating a sequence that is equidistant to all points of the tree 
[9, 83].  The ancestral approach is based upon the theoretical ancestor sequence that gave rise to 
all sequences of a particular tree [9, 83].  In addition, the population of these sequences can also 
be aligned to make a consensus sequence by assigning the most common amino acid located at 
each position [9, 83].  Generation of hybrid consensus sequences of the Envgp120 constant regions 
have been used in conjunction with the variable regions based upon a single viral isolate [84].  
HIV vaccines based upon each of these centralized methods are in development.   
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Figure 4 Centralized Vaccines.  
This figure demonstrates the three methods of developing a centralized vaccine.  (A.)  Ancestral 
vaccine.  This method of centralization utilizes the theoretical ancestor that gave rise to the 
phylogenetic tree.   The location of the ancestral vaccine is shown with a black dot.  (B.) Center-
of-the-tree.  This method of centralization generates a sequence that is equidistant to all points of 
the phylogenetic tree.  The approximate location of the vaccine sequence is shown with a black 
dot.  (C.) Consensus vaccine.  A consensus sequence was generate from the seven sample 
envelope sequences by assigning the most common amino acid at each position in the amino acid 
sequence.    
 
 
The development of centralized sequences is highly dependent on the quality of the 
starting sequence library.  The center-of-the-tree and ancestral methods utilize a phylogenic tree 
that is constructed based on assumptions created to fill gaps generated by incomplete sampling of 
the viral population.  If these assumptions are incorrect it will alter the resulting centralized 
sequence to also be incorrect.  The greatest degree of problems comes with the development of 
ancestral sequences, as they are the most heavily influenced by the assumptions used to generate 
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a phylogenic tree.  Sampling for the development of ancestral sequences also require including 
sequences from older samples.  These samples are often difficult to obtain and are representative 
of only a small population of viruses thus affecting the resulting sequence.  A consensus 
sequence can also be biased by the sampling of the viral population.  If this sampling only covers 
a small population, the resulting sequence will be unevenly weighted to that sample.  Each 
centralized strategy is dependent on developing an unbiased, large database of sequences.  
Through the development of such databases the short comings of these methods can be 
overcome.   
 
1.8.1 Centralized HIV-1 Envelope Sequences.  
The three methods of developing centralized sequences are currently being used to overcome the 
challenges of viral diversity in HIV-1.  The most common approach has been through the use of 
consensus sequences.  However, any of the three designs may miss epitopes in any given 
immunogen therefore combining several consensus sequences has advantages for covering as 
many epitopes within a diverse immunogen, such as the HIV-1 envelope.  Recently, vaccine 
strategies utilizing consensus and ancestral Env epitopes have proven potent inducers of both 
humoral and cellular immunity [85-89].  The initial generation of centralized sequences were 
tested to ensure that these artificial genes were able to express functional products [85, 90-94].  
The majority of centralized sequences use codon optimization to enhance gene expression.  This 
technique generates a sequence using the optimum codon for a given species to maximize protein 
expression [95].  Codon optimized envelopes are cleaved into Envgp120 and Envgp41 at the surface, 
similar to native Env proteins [91-92].  Centralized envelopes form trimers that facilitate binding 
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to CD4 and co-receptors, as well as establish infection in vitro when pseudotyped onto viral 
backbones [85, 91-92, 94].  Other consensus HIV-1 proteins such as Tat, Rev and Nef have also 
been shown to efficiently express and be naturally processed further demonstrating the utility of 
consensus sequences [93].   
Centralized Env vaccines based upon geographic regions, specific Group M clades, 
multiple clades and the entire Group M have been investigated [84-85, 90-94, 96-104].  Regional 
centralized vaccines based upon viruses circulating in specific geographical regions of Africa 
[99, 103] were designed to match the viral strains which caused over 70% of the infections 
within an area, such as Kenya [99].  This vaccine consisted of a consensus CAp24/MAp17, as well 
as CTL epitopes derived from a clade A Env.  Strong cellular immune responses were observed 
in murine studies and immunogenicity was demonstrated in early clinical trials.  A vaccine 
designed for eastern and central Africa consisted of a consensus clade A Tat, Reverse 
Transcriptase, Nef and Envgp41 [103].  This vaccine induced strong cellular responses to each of 
the above components; however it did not elicit antibodies, which may limit its effectiveness in 
protective efficacy.   
1.8.2 Vaccines based upon sequences from a single clade. 
Centralized vaccines targeted against clade B or C gene products elicit strong cellular and 
humoral immune responses [91-93].  A DNA vaccine based upon centralized clade C sequences 
expressing Tat, Rev and Nef elicited cellular immune responses that were equal to immunity 
elicited by corresponding vaccines based upon wild-type, primary sequences [93].  In addition, 
ancestral and consensus envelope-based vaccines for clade C are highly immunogenic eliciting 
both strong cellular and humoral immune responses [92].  These centralized Env-based vaccines 
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elicited antibodies that recognized an increased number of clade C isolates compared to vaccines 
composed of wild-type sequences.  Consensus clade B Envs elicit an increased breadth of 
antibody recognition and virus neutralization as compared to primary isolates[91].  Interestingly, 
similar cellular responses were elicited by both clade B and C vaccine approaches [92].  These 
results indicate that vaccines based upon a centralized sequence can increase the breadth of 
immune responses, thereby allowing for an increase in the coverage of circulating viruses. 
 
1.8.3 Vaccines based upon sequences from multiple clades. 
Centralized vaccines based upon the entire Group M set of isolates strive to elicit immunity 
against various proteins in viral isolates across clades [84-85, 94, 102].  A group M consensus 
Env vaccine induced both cellular and humoral immune responses [84-85, 94].  These vaccines 
induce immune responses that recognize both clade B and C cellular epitopes, as well as 
antibodies that neutralize isolates in both clades.  Compared to vaccines using Envs derived from 
wild-type clade A, B, and C isolates, the consensus M Env vaccine elicited higher titer immune 
responses within each respective clade than vaccines based upon the wild-type sequences [84].  
These results indicate that a group M consensus vaccine can generate both high titer and broader 
immune responses that may elicit protection against current and emerging HIV isolates.   
In contrast to a single consensus M Env strategy, a vaccine based upon Env sequences 
(consensus or ancestral) from multiple clades (A, B, C, F, G, and H) is currently in pre-clinical 
testing [102].   This DNA vaccine is composed of rev, nef, tat, and gag consensus sequences 
derived from clades A, B, and C and an ancestral sequence derived from clades F, G, and H 
[102].  This vaccine was given along with a second vaccine which encoded known cellular Env 
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and Pol epitopes [102].  In mice, this vaccine strategy elicited strong cellular responses to Gag 
and Env that protected against murine leukemia virus (MuLV) with envelopes derived from 
clade A and clade B viruses. Overall, a multiclade centralized vaccine strategy elicits immune 
responses that recognize multiple HIV proteins from multiple clades.  These vaccines 
demonstrate that group, clade, and regional centralized vaccines are immunogenic and that each 
type of vaccine is able to elicit increased coverage of viral isolates compared to wild-type based 
vaccines.   
 
1.8.4 Vaccines based upon scrambled sequences. 
Consensus methods are also being used to deliver whole genome vaccines.  The synthetic 
scrambled antigen vaccine (SAVINE) is based on a weighted consensus genome of clades A, B, 
C, and E [104].  The SAVINE vaccine is a novel use of centralized sequences.  The vaccine is 
divided into three expression plasmids expressing scrambled peptides encompassing all the HIV 
gene products.  SAVINE was designed using a consensus genome sequence.  The HIV proteins 
were then divided into 30-mer peptides overlapping by 15 amino acids.  These peptides were 
expressed as a single polypeptide from sequences that were randomly joined into a single cDNA.  
Due to the size of this cDNA, it was divided into three separate open reading frames (ORF).  
Each of the ORFs contained multiple small sections of various HIV proteins, thereby resulting in 
a single protein that presents multiple epitopes from every protein of the virus.  The SAVINE 
vaccine is highly recognized by HIV-1 positive patient sera demonstrating that the SAVINE 
vaccine presents epitopes, even though it does not encode any natural forms of HIV 
proteins[104].  The SAVINE vaccine is highly immunogenic inducing strong cellular responses 
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in mice [104].  The advantage of the SAVINE vaccine is it can present epitopes from all of the 
HIV gene products without expressing a complete HIV protein.   
1.9 POLYVALENT VACCINES 
An alternative strategy to centralized sequences is the use of mixtures of the same immunogen 
from different isolates.  These polyvalent vaccines aim to increase the coverage of the vaccine by 
combining multiple components into a single vaccine.  This strategy has been used successfully 
against infectious disease pathogens, such as pneumococcus, poliovirus and influenza virus 
[105].  Multiple methods for making a polyvalent HIV vaccine have been used (Fig 5).  One 
method of making a polyvalent vaccine is to include multiple components of the virus together in 
the vaccine.  These methods are not designed to increase the coverage of viral isolates, but are 
instead to increase the breadth of the immune responses against a single isolate by eliciting 
immune responses to multiple components.  The second method is to use antigens from multiple 
viral isolates.  These vaccines can be developed using either single antigens or multiple antigens 
from multiple isolates.  In this way a single vaccine can employ both methods of making a 
polyvalent vaccine. 
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Figure 5 Polyvalent Vaccines. 
This figure demonstrates the three main methods of developing a polyvalent vaccine.  (A.) Single 
component vaccine. These polyvalent vaccines are composed of a single repeated component 
shown as an oval.  These vaccines can be based on a single clade shown in blue or multiple 
clades as demonstrated by multiple colors.  (B.) Multiple component vaccine.  These polyvalent 
vaccines are composed of two or more target proteins and can also be based on single or multiple 
clades.  One antigen is shown as a square with the second antigen being shown as an oval.  (C.)  
Polyvalent Peptide vaccines.  These vaccines are designed to present the most common cellular 
epitopes from a population of sequences to the immune system.  The different colors represent 
different epitopes.    
 
1.9.1 Polyvalent Vaccines based upon sequences representing a single protein within a 
single clade. 
The simplest polyvalent vaccines are those consisting of multiple repeats of a single protein.  The 
Env immunogen has been the main focus of this type of polyvalent vaccine due to its high 
sequence diversity using envelopes from a single clade or from multiple clades.  Polyvalent 
vaccines containing either four or five clade B envelopes protected vaccinated monkeys against 
SHIVDH12 infection and neutralized a greater number of viral isolates than the monovalent 
vaccines, but this increased recognition was primarily restricted to the viral isolates included in 
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the vaccines [66].  These results indicate that, while a polyvalent vaccine can increase the 
breadth of a vaccine, this breadth may be limited.  Both the monovalent and polyvalent vaccine 
groups containing the challenge strain elicited greater protection than either the monovalent or 
polyvalent vaccine, which did not contain the SHIVDH12 Env. These results indicate a direct link 
of neutralizing antibody titers to protection against SHIVDH12 infection [66].  In addition to 
neutralizing antibody, other immune components contributed to protection.  Monkeys vaccinated 
with the polyvalent vaccine without the SHIVDH12 Env had lower plasma viremia than monkeys 
vaccinated with the matched monovalent vaccine [66].  These results, along with other studies 
[106], indicate that polyvalent Env vaccines elicit broader cellular immune responses that 
partially control viral infection.  Even a polyvalent vaccine composed of 14 Envs induced 
stronger cellular and humoral responses than a monovalent vaccine [106].  Interestingly, even 
though this vaccine was composed of exclusively clade B envelopes, it generated cellular 
immune responses which recognized epitopes from clades C and A/E viruses [106].  Therefore, a 
polyvalent vaccine composed of Envs from a single clade can induce broader humoral and 
cellular immune responses than a monovalent vaccine, and these responses may also recognize 
viral isolates or epitopes from different clades. 
 
1.9.2 Polyvalent Vaccines based upon sequences from different clades. 
To address the worldwide diversity of HIV, polyvalent vaccines composed of envelopes from 
different clades are in pre-clinical testing.  A majority of these studies use polyvalent vaccines 
composed of isolates from clades A, B, and C [107-109] and one study used isolates from clades 
A, B, C, D, and E [110].  These multiclade polyvalent vaccines induce broader neutralizing 
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antibodies than monovalent vaccines against each clade [107-110].  The multiclade vaccines also 
increase the breadth of cellular immunity compared to a monovalent vaccine [108-109].  
Envelope only vaccines using either multiclade or single-clade polyvalent strategies increase the 
breadth of both cellular and humoral immunity against Env.  This approach may be feasible for 
other HIV antigens or immunogens from other viruses with a high degree of diversity.   
 
1.9.3 Polyvalent Vaccines based upon sequences representing multiple viral proteins. 
To target a wider range of HIV proteins, polyvalent vaccines incorporating multiple Env isolates 
as well as other viral proteins have been constructed to address the Env sequence diversity while 
combining these immunogens with other viral targets.  These vaccines increase the breadth of 
cellular and humoral immune responses to envelope similar to the increase observed with Env 
only polyvalent vaccines [111-119].  In addition, these vaccines elicited robust immune 
responses against Gag epitopes [111-119] and several of these vaccines protected monkeys 
against SHIV infections [115-116].  One of the limitations of these challenge studies was the use 
of a challenge strain that was homologous to one of the Env isolates within the polyvalent 
vaccine [115-116], therefore, it is unclear if these vaccines will protect against a truly 
heterologous virus.  A recent clinical phase 1 trial using a polyvalent vaccine incorporating Env 
from clades A, B, C, and E, as well as a Gag p24 from clade C induced strong cellular immune 
responses against A, B, C, and E envelopes, as well as Gag epitopes [119].  Antibody binding 
and neutralization were observed against a wide range of viral isolates from clades A, B, C, D, 
and E [119].  These encouraging results indicate that a polyvalent HIV-1 vaccine is a viable 
vaccine strategy for humans. 
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1.9.4 Polyvalent Vaccines based upon Env sequences to increase the breadth of cellular 
immunity.   
A modified polyvalent vaccine, designed for optimum coverage of potential T-cell epitopes, 
utilizes a large population of sequences similar to those used in centralized sequence design 
[120].   These populations are used to generate mosaic sequences by using recombination events 
that are designed to generate a sequence, which provides optimum coverage of the most common 
9-mer epitopes for a given target protein.  These mosaic sequences exclude any rare 9-mer 
epitopes, so only the most likely epitopes are included in the final product.  These 
computationally-derived mosaic vaccines were compared to both polyvalent vaccines using 
natural strains and consensus vaccines.  The computational data indicates that the optimized 
polyvalent mosaics will elicit broader coverage of potential T-cell epitopes than either natural 
polyvalent or consensus vaccines [120], but these assumptions still need to be tested in animal 
models to determine if the computational increase in T-cell epitope coverage will result in 
increased protection or immunological recognition.  This study does demonstrate a new method 
of designing future vaccines through the use of computational methods. 
Another modified polyvalent strategy designed to target multiple clades utilizes 
sequences from 21 clade A, 128 clade B, 51 clade C, 17 clade D, and 33 clade E isolates to 
generate 96 lipidated and 80 non-lipidated peptides [121].  These peptides represent the five 
hypervariable regions of the HIV-1 gp120 and the two variable epitopes in HIV-1 Gag [121].  
The peptides were combined and delivered subcutaneously to Cynomolgus macaques and 
humanized HLA-A2.1 mice.  The vaccine elicited strong CD4
+
 and CD8
+
 T-cell responses that 
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were directed to isolates from clades A-E demonstrating that a multiclade polyvalent vaccine can 
elicit cellular immune responses to viruses from each of the clades included in the vaccine.  Even 
though this vaccine was designed to elicit mostly cellular immune responses, moderate humoral 
responses were also observed.  Low levels of binding antibodies were observed against the 
vaccine peptides, as well as primary Env isolates from clades A-E.  Moderate neutralization was 
observed against T-cell line adapted virus with weak neutralization observed against a few 
primary isolates [121].  Viral challenges were completed in humanized mice against a 
recombinant vaccinia virus expressing HIV-1IIIB Gag/Pol/Env proteins.  Vaccinated mice had a 
2-3 fold reduction in viral titer demonstrating control and clearance of infection [121].  It is 
unclear if this challenge model can be correlated to non-human primate challenge systems.  
Together, all of polyvalent vaccines demonstrate that there is not a loss of immunogenicity when 
additional HIV targets are added to the vaccine.  This is important as it is unlikely that a vaccine 
which focuses on only one target of HIV will be successful in the long term due to the high 
mutation rates of HIV.   
1.10 HIV-1 CLINICAL TRIALS 
The recent apparent failure of the Merck HIV-1 vaccine trial has led many to question our ability 
to develop an effective vaccine.  The results of these trials have been extensively reviewed 
elsewhere and will only be mentioned briefly as they apply to the development of broadly 
reactive vaccines (see reviews [122-123]).  The vaccines tested in these trials were designed 
using single isolates.  They therefore were only able to generate limited reactivity against 
heterologous viruses.  These vaccines were able to protect against homologous infections in non-
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human primates, but proved to be ineffective against human infections.  This is not because the 
vaccines are not inducing strong immune responses in humans, but is likely due to the fact that 
the infecting viruses are no longer homologous to the vaccine.  The recent successful Thai study 
was based on three separate Env isolates as well as Gag and Pol antigens[124].  This formulation 
likely led to the development of a more broadly reactive immune response.  This vaccine was 
focused on the development of antibody responses to the different Env components indicating 
the possibility of an effective antibody based vaccine.  Initial results from this study do indicate 
that the vaccine did not have any effect on post-infection viral levels or immune responses.  This 
may be due to the fact that antibody responses will mostly work at blocking the initial infection 
of the virus, but if an infection is established the antibody responses are not sufficient to clear the 
virus.  Therefore further work is needed to continue the development of these broadly reactive 
vaccine strategies and to bring these strategies forward into clinical trials.         
1.11 CONCLUSION 
Any future HIV-1 vaccine should be broadly reactive.  This study has chosen to focus on the 
development of an Env-based HIV-1 vaccine.  The reason that envelope was chosen was because 
it has been previously shown that antibody responses to Env if present in sufficient quantities are 
capable of blocking HIV-1 infection.  These antibody responses are capable of sterilizing 
immunity such that virus infection is never established and the exposed individual remains free 
of residual virus.  The first step in this work was to determine the best method for the 
presentation of Env as an immunogen.  Once the best presentation, method was identified two 
methods of developing broadly reactive immune responses were compared to determine which 
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method induces the broadest range of Env recognition.  The consensus method was selected from 
the centralized vaccine techniques as this technique is least limited by computational design and 
is better able to resemble a contemporary early viral isolate than either center-of-the tree or 
ancestral methods.  The polyvalent method was selected as it is a well established technique that 
has been used in multiple vaccines against other diseases.  Only early Env isolates were included 
within the polyvalent method as these isolates are more similar to transmitted viruses than late 
stage isolates.  The consensus and polyvalent vaccines were also tested for their ability to protect 
against a heterologous viral challenge as it is currently unclear as to what degree of breadth is 
needed to facilitate protection against heterologous viral strains.   
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2.0  SPECIFIC AIMS 
2.1 OVERALL DESIGN AND RATIONALE 
The overall aim of this project was to develop a broadly reactive HIV-1/AIDS vaccine.  The vast 
diversity of HIV-1 makes it highly unlikely that a single primary isolate will be able to induce 
immune responses that will be cross-reactive against the breadth of possible viral isolates.  The 
focus of these studies is the development of an envelope-based vaccine that will be able to 
induce the greatest breadth of humoral and cellular immune responses. 
2.1.1 HIV-1 clade B/R5-tropic vaccine  
The majority of individuals in the United States and Western Europe are infected with HIV-1 
clade B strains.  Viral transmission is almost always completed by R5-tropic isolates.  For this 
reason the vaccines were developed to express clade B, R5 isolates that were isolated soon after 
infection.  It is thought that these isolates will be better able to mimic transmitting viruses 
thereby generating greater protection.  Clade C viral isolates were also investigated to determine 
the cross-clade reactivity of the vaccines from different clades.  If cross-clade protection is not 
observed it may be necessary to develop multiple clade specific vaccines to best protect 
individuals from the range of HIV-1 worldwide.   
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2.1.2 Polyvalent vaccines 
Polyvalent vaccines in other systems have been shown to increase the breadth of the immune 
responses compared to single isolate vaccines.  The use of multiple isolates allows for the 
generation of immune responses to epitopes common to all isolates found in the vaccine as well 
as to epitopes found in only a single isolate.  This generates immune responses that are able to 
recognize a greater number of epitopes thereby increasing the likelihood of being able to 
recognize an epitope or epitopes from an infecting isolate.   
2.1.3 Consensus vaccines 
Consensus vaccines are generated by developing an artificial sequence that matches the most 
common amino acids at each position in the antigen of interest.  It is thought that this will 
technique will be able to generate an immune response that recognizes epitopes found in most 
isolates that would be encountered.  Whereas a single isolate would generate immune responses 
to epitopes that may be unique, a consensus vaccine would generate immune response to 
epitopes common to most isolates.  This would facilitate protection against a greater breadth of 
isolates than a given single isolate. 
2.1.4 Mucosal vaccination of particulate immunogens  
HIV-1 is primarily transmitted through the mucosal route.  A protective vaccine must induce a 
mucosal immune response to block infection at the site of entry.  Mucosal immunization can 
induce immune responses at mucosal sites as well as systemically, but systemic immunization is 
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often unable to induce responses at mucosal sites.  Therefore, a mucosally delivered HIV-
1/AIDS vaccine would be best able to induce protection if delivered through a mucosal route.  
The mucosal route chosen for this study was nasal administration.  Vaccines delivered 
nasally can be phagocytosed by M cells in the nasal lumen and then directly deposited to the 
NALT via M cell transcytosis, which preferentially drains into cervical lymph nodes.  This 
process generates a strong immune response in the respiratory track.  More importantly for HIV-
1 transmission, it is also able to induce strong immune responses in the genital mucosa at which 
a majority of HIV-1 infections occur.  Systemic immune responses are also established providing 
protection if the infection is not stopped at the mucosal surface.   
2.1.5 CpG Oligonucleotides  
Synthetic oligodeoxynucleotides contain unmethylated CpG motifs that are recognized by Toll-
like receptor 9.  CpGs induce an inflammatory state in dendritic cells and B cells increasing 
antigen uptake and processing thereby facilitating a stronger immune response.  CpGs have also 
been shown to work as a strong adjuvant when given via the nasal route.   
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2.2 OVERALL AIM 
 To determine the best strategy for development of a broadly reactive and protective  Env–based 
HIV-1/AIDS vaccine. 
 Hypothesis: A virus-like particle based- Consensus Envelope vaccine will generate the greatest 
breadth of humoral and cellular immunity facilitating protection against heterologous viral 
challenge.  
2.3 SPECIFIC AIM 1 
To determine if soluble forms of Env elicit similar immune responses as native, membrane 
bound Env. 
Hypothesis: Envelope expressed on the surface of a virus-like particle elicits broader humoral 
and stronger cellular immune responses than soluble gp120 monomers and soluble gp140 
trimers. 
2.4 SPECIFIC AIM 2 
To compare the breadth of cellular immunity elicited by consensus HIV-1 VLP and Polyvalent 
HIV-1 VLP vaccines. 
Hypothesis:  A Consensus VLP vaccine will elicit a broader cellular immune response than a 
polyvalent VLP. 
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2.5   SPECIFIC AIM 3 
To compare the breadth of humoral immunity elicited by consensus HIV-1 VLP and Polyvalent 
HIV-1 VLP vaccines and to determine the protective effect of these vaccines against a 
heterologous viral challenge. 
Hypothesis: Polyvalent and Consensus vaccines will provide protection against an intravaginal 
SHIVSF162p4 challenge with the Consensus B VLP vaccine eliciting the greatest breadth of 
immunity. 
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3.0     SPECIFIC AIM 1 
Membrane embedded HIV-1 envelope on the surface of a virus-like particle elicits broader 
immune responses than soluble envelopes 
 
 
 
 
 
 
 
 
This chapter was modified with permission from: 
Sean P. McBurney, Kelly R. Young, and Ted M. Ross 
Membrane embedded HIV-1 envelope on the surface of a virus-like particle elicits broader 
immune responses than soluble envelopes 
Virology. 2007 Feb 20;358(2):334-46 
Copyright © 2006 Elsevier Inc. 
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3.1 FOREWORD 
The work described in this aim was completed with the assistance of Kelly Young.  Dr. Kelly 
Young completed the first set of mice done for this study, as well as evaluating the initial gp120 
binding and cellular immune responses from this group.  Two additional groups, as well as all 
other immunological testing, were completed by Sean P. McBurney. 
 
3.2 ABSTRACT 
Virally regulated HIV-1 particles were expressed from DNA plasmids encoding Gag, protease, 
reverse transcriptase, Vpu, Tat, Rev, and Env. The sequences for integrase, Vpr, Vif, Nef, and 
the long terminal repeats (LTRs) were deleted. Mutations were engineered into the VLP genome 
to produce particles deficient in activities associated with viral reverse transcriptase, RNase H, 
and RNA packaging. Each plasmid efficiently secreted particles from primate cells in vitro and 
particles were purified from the supernatants and used as immunogens. Mice (BALB/c) were 
vaccinated intranasally (day 1 and weeks 3 and 6) with purified VLPs and the elicited immunity 
was compared to particles without Env (Gagp55), to soluble monomeric Envgp120, or to soluble 
trimerized Envgp140. Only mice vaccinated with VLPs had robust anti-Env cellular immunity. In 
contrast, all mice had high titer anti-Env serum antibody (IgG). However, VLP-vaccinated mice 
had antisera that detected a broader number of linear Env peptides, had anti-Env mucosal IgA 
and IgG, as well as higher titers of serum neutralizing antibodies. VLPs elicited high titer 
antibodies that recognized linear regions in V4-C5 and the ectodomain of gp41, but did not 
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recognize V3. These lentiviral VLPs are effective mucosal immunogens that elicit broader 
immunity against Env determinants in both the systemic and mucosal immune compartments 
than soluble forms of Env. 
 
3.3 INTRODUCTION 
The ultimate goal of an AIDS vaccine is to elicit potent cellular and humoral immune responses 
that will result in enduring, broadly protective immunity (reviewed in [105] and [125]). While 
much effort has focused on elucidating the mechanisms and specificity of cellular immune 
responses, less is known about virus-specific antibody responses. It has been well established 
that cellular immune responses mediate viral control during the primary infection and maintain 
the viral set point in chronic infection [126].  However, administration of human monoclonal 
antibodies passively protects against virus exposure in the HIV-1/chimpanzee [127-128], 
SIV/monkey [129-130], and SHIV/monkey models [76, 131-134], demonstrating the ability of 
antibody alone to mediate protection against pathogenic virus infection. Thus, one goal of an 
AIDS vaccine should be to elicit robust and broadly reactive cellular and humoral immunity in 
both systemic and mucosal immune compartments, thereby maximizing the potential for 
protection from variant HIV-1 strains by different routes of exposure.  A particle-based 
immunogen, such as a non-infectious virus-like particle (VLP), is a promising candidate for a 
safe and effective AIDS vaccine. VLPs are defined as self-assembling, non-replicating, non-
pathogenic, and preferably genomeless particles that are similar in size and conformation to 
intact infectious virions. There are multiple combinations of viral proteins that may be used to 
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generate VLPs, however, they must contain Gag gene products in order to assemble and bud 
from cells. Envgp160 may also be processed and incorporated as trimeric spikes protruding from 
the surface of these particles. 
The VLP used in this study is expressed from a virally regulated, multi-gene DNA 
plasmid. However, unlike many other VLPs currently being tested in AIDS vaccine research, our 
VLP-DNA plasmids can express multiple viral gene products from the same cell intracellularly 
and secrete these VLPs extracellularly from primate cells from a single DNA plasmid in vivo 
[135-136].  Other multi-gene-based VLP expression systems have been developed to express 
VLPs from DNA plasmids [137-140].  While these approaches successfully elicited cellular 
immunity against VLP antigens, these VLPs elicited limited binding antibody and little, if any, 
neutralizing antibodies, even after multiple vaccinations [137-138, 140-142].  In addition, low to 
undetectable cellular or humoral immune responses were observed at mucosal sites. The lack of 
a robust antibody responses may be due, in part, to the in vivo production of particles that were 
primarily retained intracellularly and therefore these viral antigens were processed for MHC 
class I presentation. Lastly, the lack of neutralizing antibodies in these studies may be a result of 
(1) the elicitation of low antibody titers or (2) the specific envelope chosen for incorporation into 
these particles.  Over the past 20 years, multiple AIDS vaccine strategies have been developed, 
but each has failed to protect against disease (for reviews, see [105, 125, 143-145]). Early trials 
using monomeric HIV-1 envelopes, while eliciting high titer antibodies, failed to elicit antibodies 
capable of neutralizing HIV-1 in vitro. However, the role of Env appears critical for the 
induction of protective immunity in recent AIDS vaccines [146-147], which may point to other 
antibody and cellular immune mechanisms, such as antibody-dependent cytotoxicity (ADCC) 
[148-151], as important mediators of protection. Inclusion of Env in a multi-component AIDS 
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vaccine results in lower viral set points and higher CD4 counts following challenge compared to 
the same vaccines lacking Env [146-147].  Envelope on the native virion is predicted to form a 
trimer[152-154]. Thus, while neutralizing antibody responses appear to be an important 
component to elicit in an AIDS vaccine, they tend to recognize highly conformational epitopes 
on Env that may not be immunogenic in vivo. The inability of monomeric envelopes to elicit 
neutralizing antibodies is most likely due to differences in structure between monomeric forms 
of gp120 and oligomeric forms of envelope as they are expressed on the surface of a virus 
particle. Several vaccine strategies have incorporated an oligomeric/trimeric form of Env in 
order to elicit cross-reactive immunity that neutralizes viral infection [155-162].  The expression 
of trimeric Env on the surface of a particle does appear to elicit higher titers of neutralizing 
antibodies than soluble gp120 following intramuscular injection [163], even though much of the 
neutralizing antibodies were directed at membrane embedded cellular proteins. To overcome this 
problem, soluble trimers of Env have been developed. Soluble, stabilized Env trimers are 
hypothesized to mimic the trimeric structure of the envelope on the native virion and possibly 
induce conformationally dependent antibodies that recognize epitopes present only on native 
virion-associated envelopes. Several of these trimeric Env immunogens do elicit slightly higher 
titers of neutralizing antibodies than monomeric Env gp120 [157, 164-166]. Often, these 
oligomeric Env proteins are produced by eliminating the natural cleavage site recognized by 
cellular proteases [107, 162, 167-168]. The lack of elicited high titer, broadly reactive 
neutralizing antibodies by these immunogens is associated with the elicitation of primarily non-
neutralizing antibodies [158, 169-170], because these uncleaved envelopes are in non-native 
forms or are processed through different cellular pathways than cleaved forms of Env [158-159, 
171-172]. Therefore, in this study, mice were vaccinated with soluble envelopes (monomeric 
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Env gp120 or trimeric Env gp140) or trimeric envelopes that were membrane retained on an 
HIV-1 VLP to determine if the form(s) and presentation of envelope to the immune system 
influence the elicited immunity.  
3.4 MATERIAL AND METHODS 
3.4.1 DNA plasmids 
The pTR600 vaccine plasmid  [173] and the VLP expressing plasmid, pHIV-VLP, have been 
previously described [135].  Briefly, the pTR600 vector was constructed to contain the 
cytomegalovirus immediate-early promoter (CMV-IE) for initiating transcription of eukaryotic 
inserts and the bovine growth hormone polyadenylation signal (BGH poly A) for termination of 
transcription. The vector contains the Col E1 origin of replication for prokaryotic replication and 
the kanamycin resistance gene (kan
r
) for selection in antibiotic media.  
The pHIV-VLP plasmid [135] encodes for the following gene sequences: HIV-1BH10 gag–
pol (pHIVBH10 nt 112–3626) (accession number M1564) and HIV-1ADA vpu, env, rev, tat (nt 
5101–8159). Briefly, the pHIV-VLP was constructed from two subclones encoding for the 5′ end 
of the VLP gene insert (5′-ClaI and 3′-EcoRI) and a second subclone encoding for the 3′ end of 
the VLP gene insert (5′-EcoRI and 3′-NheI). Oligonucleotides corresponding to the gag–pol 
sequences were used in a PCR reaction to amplify a fragment of DNA (5′ PCR product) 
composed of the 5′ untranslated leader sequence (105 nucleotides) and gag–pol sequences (ATG 
start codon of gag to the TAG stop codon at the 3′ end of the reverse transcriptase sequence, 
pHIVBH10 nt 112–3626). Both of the 5′ and 3′ PCR products were cloned into pTR600 using 
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unique restriction enzymes sites (5′ PCR product: ClaI and EcoRI and the 3′ PCR product using 
EcoRI and NheI). The splice–acceptor sites were not mutated to allow for efficient mRNA 
processing of singly and multiply spliced messenger RNAs. The previously described safety 
mutations were introduced into the VLP vaccine insert by PCR-based mutagenesis (Stratagene, 
La Jolla, CA) to delete RT activity, RNase H activity, and packaging of RNA genome [135].   
Plasmids expressing the HIV-1NL4-3 Gag gene products only, pGagp55, were derived from 
codon-optimized sequences (phGag), as previously described [135, 174].  pGagp55 encodes for an 
immature, unprocessed HIV-1 Gag particle. The plasmids, pEnvgp120 and pEnvgp140 (FT), encode 
for soluble forms of monomeric Envgp120 or trimeric Envgp140 from the isolate ADA [156-157]. 
Each plasmid was amplified in Escherichia coli strain-DH5 alpha, purified using anion-exchange 
resin columns (Qiagen, Valencia, CA), and stored at −20 °C in dH2O. Plasmids were verified by 
appropriate restriction enzyme digestion and gel electrophoresis.  Purity of DNA preparations 
was determined by optical density reading at a wavelength of 260 and 280 nm.   
3.4.2 Transfections and expression analysis  
The monkey fibroblast cell line COS (5×10
5
 cells/transfection) was transfected with 2 μg of 
DNA using 12% lipofectamine according to the manufacturer's guidelines (Life Technologies, 
Grand Island, NY). Supernatants (2 ml) were collected and stored at −20 °C. Cell lysates were 
collected in 500 μl of 1% Triton X-100 and stored at −20 °C. Quantitative antigen capture 
ELISAs were conducted according to the manufacturer's protocol (Perkin-Elmer Life Sciences, 
Boston, MA). For Western blot analysis, 3.3% of supernatant and 1.5% of the cell lysate were 
diluted 1:2 in SDS sample buffer (Bio-Rad, Hercules, CA), boiled for 5 min, and loaded onto a 
10% polyacrylamide/SDS gel. The resolved proteins were transferred onto a nitrocellulose 
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membrane and incubated with a 1:10,000 dilution of polyclonal antisera using HIV-Ig to detect 
HIV-1 antigens diluted in PBS containing 0.05% Tween 20 and 5% nonfat dry milk. After 
extensive washing, bound human antibodies were detected using a 1:10,000 dilution of 
horseradish peroxidase-conjugated goat anti-human antiserum, followed by enhanced 
chemiluminescence (Amersham, Buckinghamshire, UK).   
3.4.3 Purification of virus-like particles and soluble envelopes 
Supernatants from COS cells, transiently transfected with plasmid expressing Gag or VLPs were 
pelleted via ultracentrifugation (100,000× g through 20% glycerol, weight per volume) for 2 h at 
4 °C. The pellets were subsequently resuspended in PBS and overlaid onto 20–60% sucrose 
gradients (11 steps, 4% increments) and ultracentrifuged for 17 h at 100,000×g at 4 °C. Eleven 
fractions (20–60%, 1 ml, weight per volume) were collected top to bottom from the gradient, and 
the proteins were precipitated with equal volumes of 20% trichloroacetic acid (TCA) and 
subjected to SDS-PAGE and immunoblotting. The viral proteins were detected by primary 
antisera via Western blot. Determination of the amount of Gag and Env protein on the particle 
was determined by ELISA, as previously described [140].  Soluble monomeric Envgp120 or 
trimeric Envgp140 was purified from the supernatant of transiently transfected COS cells by a 
lectin column and resuspended in 0.9% saline for inoculation. 
3.4.4 Immunization of mice 
Female BALB/c mice (n=6, 5–7 weeks old) were immunized at weeks 0, 3, and 6 with purified 
VLPs (40 μg total protein) and co-inoculated with phosphorothioate CpG oligodeoxynucleotides 
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(CpG ODNs, 10 μg each) via the nares. Each CpG ODN (ODN-1: 5′-
TCCATGACGTTCCTGACGTT-3′, ODN-2: 5′-TGACTGTGAACGTTCGAGATGA-3′) [175-
179] was synthesized and purified by high-pressure liquid chromatography (Sigma-Genosys, The 
Woodlands, TX, USA). The CpG ODNs were resuspended in sterile dH2O (2 μg/μl) and stored 
at −80 °C. Each purified VLP preparation was analyzed for purity by silver staining of an SDS-
PAGE and ~80–90% of the protein in the purified preparation was Gag gene products and 
therefore, mice were administered ~0.5–1.0 μg of Env per VLP immunization. Mice were 
administered VLPs in sterile PBS plus CpG ODNs into the nares of each mouse (30 μl total 
volume). Supernatants from primate cells transiently transfected with the vector, pTR600, were 
ultracentrifuged through 20% glycerol. For intranasal inoculation, the pellet was resuspended in 
sterile PBS plus CpG ODNs and inoculated into the naïve mice (equivalent volume compared to 
mice given a VLP inoculum). Mice vaccinated with Envgp140 or Envgp120 were given 1 μg or 10 
μg of protein with the same concentration of CpG ODNs in PBS. Proteins were purified from the 
supernatant of transiently transfected cells with plasmids expressing a 6×HIS-tagged envelopes 
[156-157]. Gagp24 was purified by the same ultracentrifugation procedure as VLPs.  Mice were 
administered the same amount of Gagp24 plus CpG ODNs to match the Gagp24 in the VLP 
inoculations (40 μg).  Mice were housed in compliance with USDA regulations and were 
monitored daily for weight loss, behavior, and adverse reaction. Mice were partially anesthetized 
with xylazine (20 mg/ml) and ketamine (100 mg/ml) administered subcutaneously in the 
abdomen prior to immunization. 
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3.4.5 Collection of samples 
Blood samples were collected by retro-orbital plexus puncture on day 1 and weeks 2, 5, and 8 
post-immunization on anesthetized mice. Sera samples were collected by centrifugation (5000 
rpm, 10 min) and stored at −20 °C.  Mucosal washings were collected at week 9 post-
immunization.  Vaginal lavages were collected by repeated rinsing of the vagina (200 μl) with 
sterile PBS. The lungs were excised and cut into small pieces using a sterile scalpel in sterile 
PBS (200 μl). The lung tissue pieces were centrifuged (12,000 rpm, 5 min), and supernatants 
were collected. A section of the intestines (1.3 cm) was aseptically removed and placed in sterile 
PBS (200 μl). The collected fecal samples were disrupted using a sterile pipet tip, vortexed (15 
s), centrifuged (12,000 rpm for 5 min), and the product supernatants were collected. The protein 
concentration of the fecal supernatants was adjusted to a final concentration of 1 mg/ml with 
sterile PBS. All samples were stored at −80 °C.   
3.4.6 ELISpot assays 
Spleens were harvested from vaccinated mice at week 8, and splenocytes were isolated for 
ELISpot assays, as previously described [156-157].  Briefly, splenocytes were depleted of 
erythrocytes by treatment with ammonium chloride (0.1 M, pH 7.4). Following thorough 
washing with PBS, cells were resuspended in RPMI medium with 10% fetal bovine serum 
(cRPMI). Cell viability was determined by trypan blue exclusion staining. The number of anti-
Gag, anti-Pol, or anti-Envgp160-specific murine IFN-γ (mIFN-γ) secreting splenocytes was 
determined by enzyme-linked immunospot (ELISpot) assay (R&D Systems, Minneapolis, MN, 
USA). Briefly, pre-coated anti-mIFN-γ plates were incubated (25 °C for 2 h) with cRPMI (200 
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μl) and then were incubated with splenocytes (1×106/well) isolated from vaccinated mice. 
Splenocytes were stimulated (48 h) with peptides (AIDS Reagent and Reference Program) 
representing the consensus clade B Gag or Pol regions. For Env, four pools of peptides were 
used, (1) a pool of 10 peptides representing the C1 region of Env (amino acids 32–79), (2) a pool 
of 4 peptides representing the V3 region of Env (amino acids 294–314), (3) a pool of 99 peptides 
representing the gp120 region (amino acids 52–455) or (4) a pool of 99 peptides representing the 
gp41 region (amino acids 444–840) of the consensus Group M Env protein. The V3 regions 
peptides were specific to the sequence for the isolates, MN, IIIB, the subtype B, and the 
consensus B sequences. The subtype B and consensus B match the V3 loop of ADA. Additional 
wells of splenocytes were stimulated with PMA (50 ng)/ionomycin (500 ng) or were mock 
stimulated. In addition, IL-2 was added to all wells (10 units/ml). Plates were washed with PBS–
Tween (3×) and were incubated (25 °C for 2 h) with biotinylated anti-mIFN-γ and incubated (4 
°C for 16 h). The plates were washed and incubated (25 °C for 2 h) with streptavidin conjugated 
to alkaline phosphatase. Following extensive washing, cytokine/antibody complexes were 
incubated (25 °C for 1 h) with stable BCIP/NBT chromogen. The plates were rinsed with dH2O 
and air dried (25 °C for 2 h). Spots were counted by an ImmunoSpot ELISpot reader (Cellular 
Technology Ltd., Cleveland, OH, USA). 
3.4.7 Antibody response to VLP immunizations 
Serum and mucosal samples were individually collected and tested for antibody (IgG or IgA) 
responses to Env by ELISA. HIV-1ADA Envgp120 was purified from the supernatants collected 
from 293T cells transiently transfected with a plasmid that expressed the HIV-1ADA Envgp120 
from codon optimized gene inserts. Each well of a 96-well plate was coated with 50 ng Envgp120 
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per well (4 °C for 16 h). Plates were blocked (25 °C for 2 h) with PBS containing Tween 20 
(0.05%) and nonfat dry milk (5%) and then incubated with serial dilutions of each sample (sera 
or mucosal washings) (25 °C for 2 h). Following thorough washing in PBS–Tween 20 (0.05%), 
samples were incubated (25 °C for 1 h) with goat anti-mouse IgG conjugated to horseradish 
peroxidase (HRP) diluted 1:5000 in PBS–Tween 20 (0.05%) and nonfat dry milk (5%). The 
unbound antibody was removed, and the wells were washed. Samples were incubated with TMB 
substrate (1 h), and the colorimetric change was measured as the optical density (O.D., 405 nm) 
by a spectrophotometer (Dynex Technologies, Chantilly, VA, USA). The O.D. value of naïve 
sera and sera from mice vaccinated with virus-like particles composed of only Gag gene products 
(no Env) was subtracted from the samples using antisera from vaccinated mice. Results were 
recorded as the arithmetic mean ± the standard deviation (SD). In order to measure the level of 
HIV-1 Env-specific IgG subtypes, biotinylated goat anti-mouse IgG1 or IgG2a (1:5000) 
antibodies were used to detect Env-antibody complexes.   
3.4.8 Mapping of specific antibodies by poly-L-lysine peptide ELISA  
Antibody reactivity to HIV peptides was determined using a poly-L-lysine (PLL) peptide 
ELISA, as previously described [180-182].  Briefly, the wells of Immulon 1B microtiter plates 
(Dynex Corporation, McLean, VA) were coated with 2 μg per well of PLL (Sigma, St. Louis, 
MO) diluted in 0.05 M sodium bicarbonate buffer (pH 9.6) and incubated for 1 h at 25 °C. 
Peptides were diluted to 50 μg/ml in 0.05 M sodium bicarbonate buffer (pH 9.6) were then fixed 
onto PLL-coated wells by incubating 50 μl per well overnight at 25 °C. After ~16 h, all wells 
were washed and blocked with 100 μl of glycine (1 M) followed by 0.5% nonfat dry milk/0.5% 
gelatin for 1 h each at room temperature. Serum was diluted 1:3000 in 5% nonfat dry milk and 
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incubated for 1h at room temperature. The wells were extensively washed and incubated with 
goat anti-mouse IgG-HRP diluted 1:5000 in 5% nonfat dry milk for 1 h at 25 °C. Specific 
reactivity was detected by the addition of 100 μl TMB substrate (Sigma, St. Louis, MO, USA). 
The reaction was stopped by the addition of 50 μl of sulfuric acid (1 N) and read as O.D. at 450 
nm. Antibody reactivity was then reported as the O.D. at 450 nm at 1:3000 dilution of sera. 
3.4.9 Pseudovirus preparation 
HIV-1 viral cores were pseudotyped with envelopes representing primary R5 isolates (ADA, 
YU-2, CAAN5342.A2, PVO.4, and THRO4156.18) or R5X4 isolates (89.6). Briefly, 293T cells 
were transfected with 5 μg of Env encoding plasmid and 10 μg of an Env-deficient HIV-1 
backbone vector (pSG3Δenv) using Lipofectamine 2000 (Invitrogen) [183].  Virus-containing 
supernatant was collected 48 h post-transfection, clarified of cellular debris by centrifugation 
(14,000 rpm for 10 min) and stored at −80 °C in 1 ml aliquots. TCID50 was determined using 5-
fold dilutions of virus. Eight hours prior to infection, TZM-bl cells were plated at a concentration 
of 1×10
4
 cells per well. Cells were incubated with serial dilutions of virus for 48 h at 37 °C in 
5% CO2. Cell lysates were harvested and incubated (20 min) in lysis buffer (25 mM Tris 
phosphate, pH=7.8, 2 mM DTT, 2 mM 1-2-diaminocyclohexane-N,N,N′,N′-tetraacetic acid, 10% 
glycerol, 1% Triton X-100). Infectivity was determined by measuring the relative light units 
(RLU) using a Femtomaster FB12 Luminometer (Zylux, Maryville, TN). The TCID50 was 
calculated from the RLU values.  
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3.4.10 Neutralization assay 
Antisera from vaccinated mice were tested for the ability to neutralize virus infection in vitro 
using TZM-bl cells indicator cells [183-184].  These cells express human CD4 (hCD4), human 
CCR5 (hCCR5), human CXCR4 (hCXCR4), and a luciferase reporter driven by the HIV-1 LTR. 
TZM-bl cells were cultured in cDMEM with 10% fetal calf serum (10%) (Atlanta Biologicals, 
Atlanta, GA, USA). TZM-bl cells were plated at a concentration of 1×10
4
 cells per well and 
incubated in DMEM with 10% FCS (8 h). Equal volumes of serial dilutions of each antiserum 
and pseudovirus were incubated for at least 1 h at 37 °C. Media was removed from the TZM-bl 
cells and replaced with the antiserum/pseudovirus mixture.  The cells were then incubated for 48 
h at 37 °C in 5% CO2.  Cell lysates were harvested and incubated in lysis buffer (20 min). Virus 
neutralization by mouse antiserum was determined by measuring the relative light units (RLU) 
using a Femtomaster FB12 Luminometer (Zylux, Maryville, TN). Neutralization by naïve sera 
and sera from mice vaccinated with virus-like particles composed of only Gag gene products (no 
Env) or MuLV Env was subtracted from the RLU from assays using antisera from vaccinated 
mice. All samples were tested in duplicate. 
3.5 RESULTS 
3.5.1 In vitro expression and particle purification of virus-like particles 
An HIV-1 virus-like particle expressing plasmid was constructed from a proviral genome, as 
previously described [135]. The full-length HIV-1 VLP genome expressed Gag, protease (PR), 
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reverse transcriptase (RT), Vpu, Tat, Rev, and Env gene products to produce a PR-processed, but 
immature particle. A second VLP was expressed from a Gag only codon-optimized sequence that 
produced an unprocessed, immature particle. Plasmids expressing monomeric Envgp120 or 
trimeric Envgp140 envelopes have been previously described [157].  Expression of VLPs was 
determined in vitro following transient transfection of primate (COS) cells with each DNA 
plasmid. Cell culture supernatants and lysates containing Gag gene products were detected 
following SDS-PAGE and Western blot [135].  Particles were purified from the supernatants of 
transiently transfected cells by ultracentrifugation (20–60% sucrose gradient), and collected 
fractions were analyzed for particle composition and stability. VLPs banded in the same sucrose 
fractions (32–40% sucrose, 1.14–1.18 g/cm3), as previously described for wild-type virions (Fig. 
6) [185-189]. 
 
 
 
 
 
 
 
 
 47 
 
Figure 6 Virus-like particle production by sucrose density gradient ultracentrifugation. 
Supernatants from COS cells transiently transfected with HIV VLP expressing DNA were 
concentrated through a 20% glycerol cushion and then subjected to 20–60% (w/v) sucrose 
density gradient-equilibrium gradient ultracentrifugation. Fractions were collected from top to 
bottom, precipitated with 10% TCA, and proteins were detected by Western blot analysis.  HIV 
VLP.  Percent of each sucrose fraction lane 1, 20%; lane 2, 24%; lane 3, 28%; lane 4, 32%; lane 
5, 36%; lane 6, 40%; lane 7, 44%; lane 8, 48%; lane 9, 52%. All samples were electrophoresed 
through a 10% polyacrylamide/SDS gel and transferred to a PVDF membrane or silver stained. 
Proteins were immunoblotted with HIV-1 Ig (1:10,000) and mouse anti-human IgG (1:10,000) 
and visualized by enhanced chemiluminescence. Arrows indicate bands of HIV-1 antigens. 
 
3.5.2 Cell-mediated immunity elicited by VLPs 
Mice (BALB/c) were vaccinated intranasally with (1) purified HIV-1 VLPs, (2) Gagp55 only 
particles, (3) purified soluble trimerized Envgp140, or (4) soluble monomeric Envgp120, at day 1 
and weeks 3 and 6. Collected splenocytes were stimulated in vitro with peptides specific for 
HIV-1 Gag, Pol or Env. Mice vaccinated with the HIV-1 VLPs had a robust cell-mediated 
immune response against Gag, Pol and Env. Four pools of Env peptides were used to detect 
splenocyte responses (mIFN-γ) specifically against the C1 region, the V3 region, a pool 
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representing the gp120 region of Group M consensus Env, or a pool representing the gp41 region 
of Group M consensus Env. Mice vaccinated with soluble Envs had a reduced cellular response, 
as measured by mIFN-γ production, compared to mice vaccinated with HIV VLPs (Fig. 7). 
Cellular responses against Gag elicited by HIV VLPs were statistically similar to the responses 
elicited by Gag only particles. Age-matched mice, as well as splenocytes from mice vaccinated 
with VLPs and stimulated with an irrelevant peptide or unstimulated, had few mINF-γ secreting 
splenocytes (0–7 spots) following in vitro re-stimulation (data not shown). 
 
 
Figure 7 Elicitation of interferon-γ producing splenocytes. 
ELISpots were performed on isolated splenocytes from vaccinated mice collected at week 8. 
Cells (1 × 10
6
) were stimulated independently with peptides representing four different regions 
of Env: (a) the first constant region of gp120 (C1), (b) the V3 loop region of Env (V3), (c) the 
entire gp120 region (gp120), or (d) the entire gp41 region (gp41). Peptides in the gp120 and 
gp41 peptide pools were 15mers overlapping by 11 amino acids. The C1 and V3 pools are 
described in the Materials and methods. Splenocytes were also stimulated independently with 
pools of peptides representing Gag or Pol regions. Following stimulation, cells were assayed for 
mINF-γ. Nef peptides were used as a non-specific negative control. Splenocytes stimulated with 
PMA/ionomycin had colonies too numerous to count. 
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3.5.3 VLP-bound envelope efficiently elicits anti-Env antibody 
All mice vaccinated with HIV VLPs or soluble envelopes had anti-Env antibodies against gp120 
following the first inoculation, which increased after each subsequent vaccination.  Mice 
vaccinated with soluble envelopes were administered a 10- to 100-fold higher dose of envelope 
than mice vaccinated with membrane-bound envelope on the surface of the VLPs (Fig. 8A). 
However, even though the amount of Env on the VLP was similar to the 1 μg dose of soluble 
envelope, the VLPs elicited a log higher titer of anti-Env antibodies (Fig. 8B). Mice vaccinated 
with VLPs had higher IgG2a titers compared to IgG1, indicating a T helper type 1 immune 
response. In contrast, mice vaccinated with soluble Envgp140 or Envgp120 elicited a predominantly 
IgG1 antibodies, indicating a dominant T-helper 2 response. 
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Figure 8 Anti-Env serum antibodies. 
 (A) Total serum anti-gp120 Env IgG. Serum samples were collected prior to immunization 
(week 0) and 2 weeks after each vaccination (weeks 2, 5, and 8). Each symbol represents the 
average endpoint anti-Env serum antibody titer (n = 6). (B) Symbols represent each individual 
mouse anti-Env serum IgG endpoint titer. The line represents the average titers (week 8).  
 
 
Both anti-Env IgG and IgA were detected in mice vaccinated with VLPs (Fig. 9). The 
highest titers were detected in the lungs, but anti-Env antibodies were also detected in the 
secretions of the vagina and intestine, albeit at lower titers (Fig. 9). Mice vaccinated with soluble 
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envelopes (10 μg) generally had statistically lower titers than VLP-vaccinated mice and mice 
vaccinated with a 1 μg dose of soluble Envs had undetectable mucosal anti-Env antibodies. 
 
 
 
Figure 9 Total anti-Env IgG and IgA in the mucosa. 
Anti-gp120 Env antibody titers were determined in three mucosal tissues (lungs, intestines, and 
vagina) at week 8 post-vaccination from HIV VLP- or gp140 (10 μg)-vaccinated mice. (A) IgG. 
(B) IgA. Each bar represents the average anti-Env antibody titer (n = 6). The statistical 
significance of the difference between groups was calculated by the Student's t test. 
3.5.4 Virus-like particles broaden the anti-Env antibody responses 
Serum samples were assayed for the ability to recognize individual, overlapping peptides 
representing the entire Envgp160. Sera collected from all vaccinated mice recognized greater than 
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50% of all the peptides at low levels (<0.2 O.D, less than 3-fold over background). However, 
mice vaccinated with VLPs recognized a larger number of Env-specific peptides at higher titers 
compared to mice vaccinated with soluble envelopes (Fig. 10). Sera from mice vaccinated with 
soluble envelopes bound fewer than 9 peptides with a titer that was greater than 3-fold over 
background (non-specific peptides, as well as sera from naïve mice) (Figs. 10 A and B). In 
contrast, collected sera from HIV-1 VLP-vaccinated mice recognized 40 peptides with a titer that 
was 3-fold over background (Fig. 10 C). Sera from VLP-vaccinated mice recognized peptides in 
both gp120 and gp41 and sera from mice vaccinated with gp140, which contained the ecto-
domain of gp41, did not recognize any of the peptides representing gp41. 
Even though peptides from regions throughout Env were recognized by sera from VLP-
vaccinated mice at high titers, there did appear to be hotspots of recognition. Peptides 
overlapping the cleavage site, representing the V4-C5 regions in gp120 and the amino terminal 
region of gp41, were specifically recognized by this serum (Fig. 10). Interestingly, sera from 
VLP-vaccinated mice also recognized peptides in gp41 that overlap the highly cross-reactive 
Kennedy epitope. A few specific peptides were recognized by sera from VLP-vaccinated mice to 
regions in C2. Lower titer antibodies (2- to 3-fold over background; <0.2 O.D.) recognized 
several peptides in V1, V2, and C2, but few high titer antibodies (greater than 3-fold over 
background; >0.2 O.D.) recognized peptides in V1 or V2 and no peptides were detected to V3.  
Sera from mice vaccinated with Envgp120 did detect three V3-specific peptides at high titers, but 
Envgp140-vaccinated mice did not. In contrast, numerous peptides in the V1, V2, C2, and V3 
regions were recognized by antisera at lower titers (less than 3-fold) from mice vaccinated with 
soluble envelopes (data not shown). 
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Figure 10 Location in Env corresponding to high titer induced antibodies recognizing 
linear epitopes. 
Relative peptide location in the Env amino acid sequence detected by antiserum from each 
vaccinated mouse group that had an O.D. value greater than 3-fold over background. 
Background was measured as the O.D. value against irrelevant peptide (a Nef peptide) or the 
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reactivity of sera from naïve, age-matched mice. Vaccine: (A) Envgp120 (1 µg), (B) Envgp140 (1 
µg), (C) HIV VLP. Bottom schematic displays regions of Env, the variable regions (gray), and 
the transmembrane domain (black). 
3.5.5 Neutralization activity 
Sera were examined for the ability to neutralize virus infection in vitro [184] against both 
neutralization-sensitive and neutralization-resistant viral isolates (Table 1). Sera from mice 
vaccinated intranasally with HIV-1 VLPs had antibodies that neutralized both homologous and 
heterologous virus isolates (50% inhibition, no IC90 values detected). The R5 isolates 
representing early transmission (CAAN5342.A2, PVO.4, and THRO4156.18) were more 
difficult to neutralize than YU-2 or ADA. The dual-tropic isolate, 89.6, was consistently the 
more easily neutralized isolate and the only isolate neutralized with sera from mice vaccinated 
with soluble envelopes (Table 1). Sera from mice vaccinated with Gagp24 only did not neutralize 
any of the viral isolates (data not shown). In addition, the antibodies in the sera from VLP-
vaccinated mice were specific for Env, since the sera from these mice neutralized viruses with 
HIV-1 Env and did not neutralize viruses pseudotyped the MuLV Env (Table 1). 
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Table 1 Neutralization titers 
 
a 
Antisera from vaccinated mice were incubated with each virus pseudotyped with the indicated 
viral envelopes. 
b
 CAAN=CAAN5342.A2. 
c 
THRO=THRO4156.18. 
d 
IC50 titers from sera collected at week 10. Inhibition of viral infection of TZM-bl cells was 
assessed by the additional reduction in infectivity beyond the background of sera from age-
matched naïve mice. 
 
3.6 DISCUSSION 
In this study, HIV-1 virus-like particles were expressed from a single gene insert lacking the 
sequences for LTRs, IN, Vpr, Vif, and Nef that was engineered with safety mutations in CAp24 
and RT to prevent viral RNA packaging and reverse transcriptase activity [135]. The VLPs were 
produced from a virally regulated modified proviral genome that resulted in a self-assembling, 
non-replicating, nonpathogenic, genomeless particle that was similar in size and conformation to 
intact virions. These VLP immunogens can be administered as purified particles or expressed in 
vivo from DNA plasmids/viral vectors (for reviews, see references [190-191]).  Only a few 
systems have been developed that utilize the viral regulatory mechanisms of a lentiviral genome 
to express particles in primate cells [135, 192].   
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Mice inoculated intranasally with these HIV-1 VLPs elicited robust cellular responses to 
Gag, Pol, and Env gene products (Fig. 7). Soluble forms of Env were administered at doses 10- 
to 100-fold higher than the Env on the VLP, yet elicited few cellular responses. Both VLPs and 
soluble envelopes did elicit robust anti-Env serum antibody (Fig. 8), however, mice vaccinated 
with VLPs elicited antibodies that recognized a broader number of Env-specific peptides at 
higher titers than sera from mice vaccinated with soluble envelopes (Fig. 10). In addition, only 
mice vaccinated with VLPs had high mucosal anti-Env antibodies (Fig 9). Despite similar anti-
Env IgG serum titers (Fig. 8), only mice vaccinated with VLPs had antibodies that blocked viral 
infection of neutralization-resistant viruses in an in vitro neutralization assay (Table 1). 
Therefore, the presentation of native forms of envelope in the context of a viral membrane to the 
immune system elicited significantly broader immunity than soluble forms of envelope following 
mucosal vaccination. 
The goal of this study was to determine if envelope, presented to the immune system on 
the surface of a viral particle, is a more effective immunogen than soluble forms of Env. The role 
of Env appears critical for the induction of protective efficacy by recent AIDS vaccines [146-
147].  Non-human primates immunized with Gag only vaccines do not control viral infection as 
well as the same vaccine that included Env [146].  However, the specific immune mechanism(s) 
associated with Env in those vaccines has not been determined, but most likely is associated with 
anti-Env cellular and antibody responses.   
Envelope on the native virion is predicted to form a trimer [152, 193-195].  Therefore, 
our laboratory and others have used soluble, oligomeric/trimeric forms of Env to mimic the 
proposed native trimeric structure of Env on the viral membrane in order to elicit cross-reactive 
immunity and induce conformationally dependent antibodies that recognize epitopes present only 
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on the native virion-associated envelopes [155, 157-162, 196-198].  These uncleaved oligomeric 
Env proteins do elicit marginally higher neutralizing antibody titers than monomers of Env 
gp120 when administered parenterally [157, 164-166]. The lack of high titer, broadly reactive 
neutralizing antibodies elicited by these immunogens is associated with the elicitation of 
primarily non-neutralizing antibodies [159, 169-170]. 
Even though all the vaccines in this study elicited serum anti-Env antibodies, the 
envelope-bound VLPs elicited higher titers of both mucosal antibodies (Fig. 9) and serum 
antibodies that recognized a broader range of linear Env epitopes following intranasal 
administration (Fig. 10). Similar titers were elicited using a monomeric Envgp120 or trimeric 
Envgp140 expressed in a DNA prime/protein boost by intramuscular injection [157, 199]. These 
results are supported by a recent study from Grundner et al. [197] that demonstrated Envgp140 
cleavage-defective trimers (similar to the Envgp140 trimers used in this study) are more effective 
at generating neutralizing antibodies when presented on a solid phase proteoliposomes, 
indicating that the Envgp140 trimer presented on the surface of a lipid bilayer is a more effective 
immunogen than nonmembrane-bound Env trimers. However, there are most likely considerable 
differences between cleaved Envgp160 trimers on our VLPs and uncleaved Envgp140 trimers, even 
when presented on a lipid membrane. 
Linear antibodies elicited in VLP-vaccinated mice were directed to regions in gp120 
outside V3, similar to sera from mice vaccinated with Envgp140 proteoliposomes [197].  The role 
of the V3 region in eliciting neutralizing antibodies has been controversial. Even though V3-
specific antibodies can neutralize T-cell-adapted (TCLA) HIV-1 isolates by recognizing a linear 
site (GPGR/Q), they do tend to be strain-specific [200-201]. V3-specific antibodies are often 
elicited using Envgp120 monomers due to sequence accessibility on gp120, but this region is less 
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accessible in oligomeric forms of Env [200, 202-203] and may be less accessible in primary 
HIV-1 isolates [154, 200, 204].  Even though few V3-specific linear epitopes were recognized at 
high titers by sera from mice vaccinated with VLPs, we cannot rule out that the antibodies 
recognized conformational epitopes in V3. Sera from both soluble Env- and VLP-vaccinated 
mice were tested in a concanavalin A (Con A) capture ELISA. All serum samples retained high 
endpoint dilution titers to gp120 (>1:10 000), indicating that the sera contained antibodies that 
recognized both conformational epitopes on Env, as well as linear epitopes. The elicited anti-Env 
antibodies recognized a cluster of peptides just before (V4-C5 region in gp120) and just after 
(ectodomain of gp41) the cleavage site.   
At lower titers, sera from both soluble Env- or VLP-vaccinated mice recognized peptides 
throughout gp120, including the V1 and V2 regions, however, few of the V1 and V2 peptides 
were detected at high titers. Three immunodominant peptides in V2 were detected in all VLP- 
and soluble Env-vaccinated mice (peptide 47, representing NDNTSSYRLISCNTS and peptides 
57–58, representing ILKCNDKKFNGTGPCTNVS). Even though antibodies directed to V1, V2, 
and/or V3 have been shown to be potent in neutralizing virus in in vitro infection assays [205-
207], the role of these antibodies in protection is unclear and controversial [205-206, 208-212]. 
An interesting set of peptides detected by sera from VLP-vaccinated mice was the highly 
cross-reactive Kennedy epitope (residues 731–752, SRFPDRPEGTEEEGGERDRDRS) located 
in a region classified as the intra-cytoplasmic domain (ICD) of gp41 [213]. It has been widely 
assumed that the ICD is located completely within the inner leaflet of the viral or cellular lipid 
bilayer. However, neutralizing antibodies are directed to the Kennedy epitope [213-217], and at 
least part of the Kennedy epitope, in the context of intact virions, is reactive with specific 
monoclonal antibodies and susceptible to protease digestion, consistent with ICD virion or 
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infected cell exposure. Based on antigenic properties and a theoretical structural analyses of 
Envgp41 ICD sequences from various HIV-1 clades (357 sequences), Hollier and Dimmock 
recently proposed that ICD sequences potentially form a tail loop structure supported by three β-
sheet membrane spanning domains [218]. Therefore, antibodies directed at this region in Envgp41 
would only be elicited by Envgp160 molecules found in particle-based vaccines or from Envgp160 
expressed in vivo from DNA plasmids or viral vectors. 
We chose to use a mouse model for these studies primarily because this small animal 
model allows for detailed analysis of both cellular and humoral immunity induced by these VLP 
vaccines. However, one limitation of sera collected from mice is the intrinsic high titers of non-
specific background observed in in vitro neutralization assays. Despite these limitations, sera 
collected from VLP-vaccinated mice were able to neutralize both neutralization-sensitive and 
neutralization-resistant viral isolates (Table 1). Mice vaccinated intranasally with either soluble 
monomeric Envgp120 or trimeric Envgp140 had neutralizing antibodies to only 89.6. Even though 
our laboratory and others have demonstrated that trimeric Envgp140 elicits modest levels of 
neutralizing antibodies, the lack of neutralizing antibodies from soluble Env-vaccinated mice 
may be a result of the route of inoculation [mucosal (intranasal) vs. parenteral 
(intramuscular/intradermal)]. The neutralizing capacity of sera collected from VLP-vaccinated 
mice was specific for the HIV-1 envelope, since this serum did not neutralize virus pseudotyped 
with MuLV Env (Table 1). These HIV-1 Env-specific neutralizing antibody titers were above the 
background neutralizing antibodies directed against cellular monkey proteins embedded in the 
VLP membrane, since sera from mice vaccinated with Gag only particles (no envelope) elicited 
few antibodies, which were subtracted from the final analysis.  Recently, Hammonds et al. 
recorded high levels of neutralizing antibodies to cellular embedded proteins in VLP-vaccinated 
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guinea pigs following intramuscular injection [163], but significant neutralizing titers were still 
present following depletion of the non-specific neutralizing antibodies.  The reasons for the 
differences in neutralizing capacity in the sera from these two studies are unclear, but may be 
due to the route of inoculation (intranasal vs. intramuscular), the amount of Env on each of the 
particles, the animal species used (mice vs. guinea pigs), or the phenotype of the envelope 
isolates used [183].  These differences are unlikely a result of the neutralization assay used, since 
both studies used the same TZM-bl assay [183].  No neutralizing antibodies were detected in the 
lung washes from our vaccinated mice, which may be directly due to the mouse model used or 
the low titers of mucosal antibodies detected (Fig. 9). Future studies in larger rodents (rabbits or 
guinea pigs) or non-human primates will be necessary to determine if VLPs elicit neutralizing 
antibodies in mucosal tissues. 
Why might the VLPs described in this study be such effective mucosal immunogens? 
Compared to particulate antigens, intranasal vaccination of soluble proteins, in the absence of an 
adjuvant, induces low or undetectable immune responses in rodents and primates [219].  
Intranasal immunization of VLPs induces both systemic and mucosal immunity. Soluble antigens 
can penetrate the nasal epithelium and directly interact with dendritic cells, macrophages and 
lymphocytes and then these antigens are transferred to posterior lymph nodes [220].  In contrast, 
VLPs are most likely phagocytosed by microfold epithelial cells (M cells) in the nasal lumen and 
then directly deposited to the NALT (nasal associated lymphoid tissue) via M cell transcytosis 
[81], which preferentially drains into lymph nodes. This process induces strong local (NALT) 
and distant immune responses in both peripheral and mucosal immune compartments [221].  
Soluble antigens bypass the NALT and are directly fed into superficial lymph nodes by antigen 
presenting cells in the nasal lumen resulting in a lower local immune response [221].  Therefore, 
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VLP immunogens directly interact with the mucosal immune system to elicit high titer 
immunity. Overall, the expression of Env in any HIV/AIDS vaccine may elicit a variety of 
potentially effective protective immunity depending on the structure of the protein presented to 
the immune system.  Following mucosal administration, the membrane-bound Env on the surface 
of a particle appears more effective at eliciting immunity that specifically recognizes Env on the 
native particle compared to the immunity elicited by soluble monomers or trimers of Env. 
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Comparison of the breadth of cellular immunity generated by Consensus, Polyvalent and 
Monovalent HIV-1 virus-like particle vaccines 
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4.1 ABSTRACT 
Envelope (Env) sequences from human immunodeficiency virus (HIV) strains can vary 
by 15-20% within a single clade and as much as 35% between clades.  Previous AIDS vaccines 
based upon a single isolate often could not elicit protect immune responses against heterologous 
viral challenges.  In order to address the vast sequence diversity in Env sequences, consensus 
sequences were constructed for clade B and clade C envelopes and delivered to the mouse lung 
mucosa on the surface of virus-like particles (VLP).  Consensus sequences decrease the genetic 
difference between the vaccine strain and any given viral isolate.  The elicited immune responses 
were compared to a mixture of VLPs with Envs from primary viral isolates.  This polyvalent 
vaccine approach contains multiple, diverse Envs to increase the breadth of epitopes recognized 
by the immune response and thereby increase the potential number of primary isolates 
recognized.  Both consensus and polyvalent clade B Env VLP vaccines elicited cell-mediated 
immune responses that recognized a broader number of clade B Env peptides than a control 
monovalent Env VLP vaccine in both the systemic and mucosal immune compartments.  All 
three clade C Env vaccine strategies elicited similar responses to clade C peptides.  However, 
both the consensus B and C Env VLP vaccines were more effective at eliciting cross-reactive 
cellular immune responses to epitopes in other clades.  This is the first study to directly compare 
the breadth of cell-mediated immune responses elicited by consensus and polyvalent Env 
vaccines. 
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4.2 INTRODUCTION 
The development of an effective AIDS vaccine has been hampered by the intrinsic diversity 
among circulating populations of HIV-1 in various geographical locations.  There is a need to 
develop vaccines that can elicit enduring protective immunity to variant HIV-1 strains.  Based on 
viral genetic distances and positions in phylogenetic trees, HIV-1 is divided into three separate 
groups: M, O, and N [10].  Group O infections are limited to central Africa and Group N 
infections are found in a small number of patients in Cameroon [222].  The vast majority of viral 
isolates are designated as Group M and they are responsible for the continuing worldwide AIDS 
pandemic.  Due to the diversity in amino acid sequences between isolates within Group M, this 
group is further subdivided into nine subtypes or clades (A-D, F-H, J and K) [10].  The diversity 
between isolates in different clades can vary by as much as 35%.   
The ultimate goal of an AIDS vaccine is to elicit potent cellular and humoral immune 
responses that will result in enduring, broadly protective immunity.  Over the past 20 years, a 
number of potential AIDS vaccines have elicited immune responses that decreased viral set-
points and maintained CD4
+
 T cells in vaccinated animals, but sterilizing immunity has not been 
achieved [223-226].  Often, this limited protection occurs when the challenge virus is 
homologous to the viral proteins of the vaccine [223-226].  However, these artificial challenge 
models are not reflective of human infections and therefore the diversity of HIV-1 isolates 
requires vaccine designs that elicit broadly reactive immunity.   
The greatest diversity is localized to the viral envelope glycoproteins which may reflect 
its primary role in eliciting host immune recognition and responses that result in progressive 
evolution of the envelope proteins during persistent infection.  Interestingly, while Env variation 
is widely assumed to be a major obstacle to AIDS vaccine development, there are very few 
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experimental data in animal or human lentivirus systems addressing this critical issue.  One 
method previously used to address Env variation in an AIDS vaccine is a polyvalent vaccine 
strategy [106-110, 224].  These vaccines consist of a mixture of divergent isolates of the same 
antigen administered simultaneously.  Polyvalent vaccines function by presenting a wide range 
of epitopes that cover a majority of individual strains.  Vaccines for pneumococcus, poliovirus, 
and influenza virus have used this strategy [105].  Polyvalent vaccines increase the strength and 
breadth of humoral immune responses compared to monovalent vaccines [107-109, 114-116, 
118, 227-228].  The increase in the number of immunogens, below a certain threshold, does not 
result in immune interference [229].   
More recently, centralized sequences have been developed as an alternative vaccine 
strategy to address viral sequence diversity.  These artificial sequences are designed using 
computational methods to minimize the distance between a vaccine strain and primary wild-type 
isolate.  The three main strategies for developing centralized vaccines are center of the tree, 
ancestral, and consensus (for review see [230-231]).  Each of these designs has advantages for 
vaccine development.  Consensus sequences minimize the degree of sequence dissimilarity 
between vaccine immunogens and circulating virus strains by creating artificial sequences based 
upon the most common amino acid in each position in an alignment [63, 232-236].  Recently, 
vaccine strategies utilizing consensus or ancestral HIV-1 Gag and Env sequences have proven 
potent inducers of CTL activity [86-89, 233].  These consensus Envs form native structures and 
facilitate infection via the CCR5 co-receptor [85, 90].   
In this study, monovalent, polyvalent and consensus Env vaccines were compared for the 
ability to elicit broadly reactive cellular immune responses following vaccination in mice.  Each 
set of Env vaccines was generated from clade B or clade C envelope sequences.  HIV-1 virus-
 66 
like particles (VLP) were used to deliver these Env sequences to the immune system in their 
native trimeric structure on the surface of a viral particle and the elicited immune responses were 
compared for the breadth of Env reactivity. 
4.3 MATERIALS AND METHODS 
4.3.1 Envelope gene sequences 
The wild-type HIV-1 subtype B and C and consensus full-length env gene sequences were 
derived from the most common amino acids found at each location within the Env gene from 
over 200 isolates for each clade (Los Alamos National Laboratory; www.lanl.gov).  Consensus 
genes were generated from the derived consensus sequences by GeneArt (Burlingame, CA)  in 
Contemporary subtype B and C env genes were cloned by polymerase chain reaction (PCR) 
amplification from Envgp160 plasmids obtained from the AIDS Reagent and Reference Program 
(National Institutes of Health).  Primers were designed to insert a 5’ XhoI site and a 3’ NheI site 
to facilitate cloning into the VLP vector.  The nucleotide sequences of the env genes are 
available under accession numbers PVO.4 (AY835446), AC10.0.29 (AY835446), RHPA4259.7 
(AY835447), SC422661.8 (AY835441), Du151.2 (AY835441), CHN19 (AF268277), and 
ZM214m.PL15 (DQ388516). 
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4.3.2 DNA Plasmids 
The pTR600 vaccine expression plasmid [237] and the HIV-1 VLP expressing plasmid, have 
been previously described [238]. Briefly, the pHIV-wtVLPADA plasmid encodes for the 
following gene sequences: HIV-1BH10 gag–pol (pHIVBH10 nt 112–3626) (accession number 
M1564) and HIV-1ADA vpu, env, rev, tat (nt 5101–8159).  Safety mutations were engineered into 
Gag to prevent viral RNA packaging [239-240] and RT to prevent reverse transcriptase and 
RNase H activity (pHIV-VLPADA) [23, 241-242].  Each VLP was expressed from a 
cytomegalovirus immediate-early promoter (CMV-IE) for initiating transcription of eukaryotic 
inserts and the bovine growth hormone polyadenylation signal (BGH poly A) for termination of 
transcription. Consensus Env VLPs were constructed by substituting ADA env with the 
consensus env sequences from the consensus clade B and C envelopes (LANL database). The 
primary isolate VLPs were constructed by substituting ADA env with the primary env sequences.  
Plasmids expressing the HIV-1NL4-3 Gag gene products only, pGagp55, were derived from codon-
optimized sequences (phGag), as previously described [238, 243].  pGagp55 encodes for an 
immature, unprocessed HIV-1 Gag particle.  Each plasmid was amplified in Escherichia coli 
strain-DH5 alpha, purified using anion-exchange resin columns (Qiagen, Valencia, CA), and 
stored at -20
o
C in dH2O. Plasmids were verified by appropriate restriction enzyme digestion and 
gel electrophoresis. Purity of DNA preparations was determined by optical density reading at a 
wavelength of 260 and 280 nm. 
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4.3.3 Purification of virus-like particles. 
Supernatants from COS cells, transiently transfected with plasmid expressing Gag or VLPs were 
purified via ultracentrifugation (100,000 X g through 20% glycerol, weight per volume) for 4 h 
at 4
o
C. The pellets were subsequently resuspended in PBS and stored at -20
o
C until use.  Protein 
concentration was determined by Micro BCA
TM
 Protein Assay Reagent Kit (Pierce 
Biotechnology, Rockford, IL, USA).   
4.3.4 Expression analysis 
For Western blot analysis, 1 µg of purified VLP was diluted 1:2 in SDS sample buffer (Bio-Rad, 
Hercules, CA), boiled for 5 min, and loaded onto a 10% poly-acrylamide/SDS gel. The resolved 
proteins were transferred onto a nitrocellulose membrane (Bio-Rad) and incubated with a 1:500 
dilution of HIV-1IIIB rabbit anti-gp120 polyclonal sera (Advanced Biotechnologies Inc, 
Columbia, MD) in PBS containing 0.05% Tween 20 and 5% nonfat dry milk.  After extensive 
washing, bound rabbit antibodies were detected using a 1:5000 dilution of horseradish 
peroxidase-conjugated goat anti-rabbit anti-serum and enhanced chemi-luminescence 
(Amersham, Buckinghamshire, UK).  The Western blots were scanned and densitometry was 
determined using ImageJ software (http://rsbweb.nih.gov/ij/).  Expression levels were 
normalized to ConB VLP as it had the highest expressions levels.   
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4.3.5 Immunization of mice.  
Female BALB/c mice (5–7 weeks old) were immunized at weeks 0, 4, and 8 with purified VLPs 
(20 µg total protein) and co-inoculated with phosphorothioate
 
CpG oligodeoxynucleotides (CpG 
ODNs, 5 µg each, total of 10 µg) via the nares in a total volume of 30 µL.  Each CpG ODN 
(ODN-1: 5'-TCCATGACGTTCCTGACGTT-3', ODN-2: 5'-
TGACTGTGAACGTTCGAGATGA-3') [244-248] was synthesized and purified by high-
pressure liquid
 
chromatography (Sigma-Genosys, The Woodlands, TX, USA).  The
 
CpG ODNs 
were resuspended in sterile dH2O (2 g/µl) and stored at -20C.  The composition of each 
purified VLP preparation is approximately 80-90% Gag gene products and therefore, mice were 
administered ~0.5-1.0 µg of Env per VLP immunization.  Mice were housed in compliance with 
U.S.D.A. regulations and were monitored daily for weight loss, behavior, and adverse reaction.  
Mice were partially anesthetized with xylazine (20 mg/ml) and ketamine (100 mg/ml) 
administered subcutaneously in the abdomen prior to immunization. 
 
4.3.6 Collection of samples.   
Blood samples were collected by retro-orbital plexus puncture on weeks 0, 2, 6, and 10 post-
immunization on anesthetized mice.  Sera samples were collected by centrifugation (5,000 rpm, 
10 min) and stored at -20C.  Spleens were harvested from vaccinated mice at week 10, and 
splenocytes were isolated for ELISpot assays, as previously described [249-250].  Briefly, 
splenocytes were depleted of erythrocytes by treatment with ammonium chloride (0.1 M, pH 
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7.4). 
 
Following thorough washing with PBS, cells were resuspended in RPMI medium.  Cell 
viability was determined by trypan blue exclusion staining.    
 
4.3.7 Antibody response to VLP immunizations.   
Serum samples and lung washes were individually collected and tested for antibody (IgG) 
responses to homologous VLP by ELISA.  Each well of a 96-well plate was coated with 50 ng 
per well of the respective VLP (4°C for 16 hr).  Plates were blocked (25°C for 2 hr) with PBS 
containing Tween 20 (0.05%) and nonfat dry milk (5%) and then incubated with serial dilutions 
of each sample (25C for 2 hr).  Following thorough washing in PBS-Tween 20 (0.05%), 
samples were incubated (25°C for 1 hr) with biotinylated goat anti-mouse IgG conjugated to 
horseradish peroxidase (HRP) diluted 1:5000 in PBS-Tween 20 (0.05%) and nonfat dry milk 
(5%).  The unbound antibody was removed, and the wells were washed.  Samples were 
incubated with TMB substrate (1 hr), and the colorimetric change was measured as the optical 
density (O.D., 405nm) by a spectrophotometer (BioTek Instruments, Winooski, VT, USA).  The 
O.D. value of naïve sera was subtracted from the samples using antisera from vaccinated mice.  
Results were recorded as the arithmetic mean ± the standard deviation.   
 
4.3.8 Neutralization assay. 
Antisera from vaccinated mice were tested for the ability to neutralize virus infection in vitro 
using TZM-Bl cells indicator cells [251-252].  These cells express human CD4 (hCD4), human 
CCR5 (hCCR5), human CXCR4 (hCXCR4), and a luciferase reporter driven by the HIV-1 LTR. 
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TZM-Bl cells were cultured in cDMEM with 10% fetal calf serum (10%) (Atlanta Biologicals, 
Atlanta, GA, USA).  Infectivity was determined using serial dilutions of antisera with cells in 
complete, non-selective media in the presence of DEAE dextran (20 g/ml) (25°C for 1hr).  Cell 
lysates were harvested in lysis buffer (25mM Tris phosphate, pH=7.8, 2mM DTT, 2mM 1-2-
diaminocyclohexane-N, N, N', N'-tetraacetic acid, 10% glycerol, 1% Triton X-100) (48 h) and 
then clarified by centrifugation.  Virus neutralization by mouse antisera was determined by 
measuring the relative light units (RLU) using a Femtomaster FB12 Luminometer (Zylux, 
Maryville, TN).  Neutralization by naïve sera and sera from mice vaccinated with virus-like 
particles composed of only Gag gene products (no Env) was subtracted from the RLU from 
assays using antisera from vaccinated mice.   
 
4.3.9 ELISpot assays. 
The number of anti-Gag and anti-Env specific murine IFN- (mIFN-) secreting splenocytes and 
lung cells was determined by enzyme-linked
 
immunospot (ELISpot) assay (R & D Systems, 
Minneapolis, MN, USA).  Briefly, pre-coated anti-mIFN- plates were incubated (25°C for 1 h) 
with cRPMI (200 µl) and then were incubated with splenocytes (5 X 10
5
/well) or lung cells (1 X 
10
6
/well) isolated from vaccinated mice.  Cells were stimulated (48 h) with peptides (15mers 
overlapping by 11 amino acids) representing the consensus clade B HIV-1 Gag, consensus clade 
B, or consensus clade C Env proteins (NIH ARRRP). IL-2 was added to all wells (10 units/ml). 
Control wells were stimulated with PMA(+) (50 ng)/ionomycin (500 ng) or were mock 
stimulated(-).  Plates were washed with PBS-Tween (3X) and were incubated (37°C for 48 h; 5% 
CO2) with biotinylated anti-mIFN- and incubated (4C for 16 h).  The plates were washed and 
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incubated (25°C for 2 h) with streptavidin conjugated to alkaline phosphatase.  Following 
extensive washing, cytokine/antibody complexes were incubated (25°C for 1 h) with stable 
BCIP/NBT chromogen.  The plates were rinsed with dH2O and air dried (25°C for 2 h).  Spots 
were counted by an ImmunoSpot ELISpot reader (Cellular Technology Ltd., Cleveland, OH, 
USA). 
 
4.3.10 CD4 cell depletion 
CD4 cells were depleted from single cell suspensions of splenocytes from individual mice.  
Depletions were completed using the CD4 (L3T4) microbeads and an autoMACS Separator per 
manufacturer’s instructions (Miltenyi Biotec Inc., Auburn, CA).  
4.4 RESULTS 
4.4.1 Selection of wild-type and design of consensus B or C env gene sequences.  
The aim of this study was to compare the breadth of immune responses elicited by wild-type 
(individually or in a mixture) or consensus envelope sequences. The consensus (Con) B or C Env 
sequences were generated by selecting the most common amino acid at each position of a full-
length Env alignment derived from 200 subtype B or C viruses deposited in the 2005 HIV 
Sequence Database.  Each set of subtype sequences was also supplemented with env sequences 
used in a standardized neutralizing panel [183, 253].    
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The wild-type sequences used to design monovalent or polyvalent vaccines were selected 
based upon 4 criteria:  route of transmission, weeks after transmission, place of transmission, and 
neutralization phenotypes.  All Envs were chosen from isolates from patients that received the 
virus via sexual transmission.  Five of the seven isolates were transmitted by heterosexual 
transmission (M-to-F or F-to-M) and two isolates by M-to-M transmission (Table 2).  Two of the 
clade B viruses were isolated from patients living in United States, one in the Caribbean, and one 
in Europe, whereas the three clade C isolates were collected from patients living in Africa and 
Asia.  All of the isolates used in the polyvalent vaccines were collected in the acute phase of 
infection and were neutralization resistant [183, 253].  Fig. 11 A and B depicts an alignment of 
Con B and Con C Envgp160 sequences and the deduced protein sequences of the contemporary 
wild-type env sequences. One of the strains from each polyvalent vaccine was used as a 
monovalent vaccine control.  Primary and consensus clade B and C Envs efficiently bound to 
human CD4, were CCR5-tropic and facilitated infection with similar efficiency (data not shown).    
Env sequences were cloned into the HIV-1 VLP expression plasmid that contained the 
HIV-1BH10 gag–pol and HIV-1ADA vpu, env, rev, tat [238].  Following purification, each particle 
contained similar amounts of envelope (Fig. 12).  The expression of Envgp160 from each VLP 
vaccine was determined to ensure that similar doses of Env were on the particle surface and 
delivered with each VLP.   
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Table 2 Characteristics of envelopes used in the virus-like particle vaccines 
 
a
 Direction of sexual transmission: M–M male to male, M–F male to female, F–M female to male. 
b
 Length of infection is defined as time between last negative HIV-1 test and first positive HIV-1 test. 
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B. 
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Figure 11 Generation of consensus (Con B and Con C) envelopes. 
Alignment of the deduced protein sequence of full-length (unmodified) Con B Env with those of 
recently transmitted, contemporary subtypes B and C Env isolates. Sequences are compared to 
consensus gp160, with dots indicating sequence identity, and dashes indicating gaps introduced 
for optimal alignment. Potential N-linked glycosylation sites are in italics, bolded and 
underlined. The locations of the gp120/gp41 cleavage sites are indicated, as are the positions of the 
variable loops (V1–V5) and the transmembrane (TM) domain. (A) Con B. (B) Con C. 
 
 
 
Figure 12 Envelope expression on virus-like particles. 
(A) Purified virus-like particles were loaded with 1 μg of total protein in each well in a SDS-
polyacrylamide gel under reducing conditions and probed with rabbit anti-HIVIIIB gp120 
polyclonal sera. The level of envelope expressed in the VLP was determined by comparison of 
the density of the bands observed in the Western blot. Levels are shown as percent of envelope 
as compared to Con B. 
4.4.2 Antibodies elicited by VLP vaccines. 
Groups of mice (BALB/c) were vaccinated with either 1) the consensus Env VLPs (Con B or 
Con C) individually, 2) wild-type Env VLPs individually (monovalent:  PVO.4 or DU151), or 3) 
a mixture of wild-type Env VLPs (Poly B or Poly C).  As a control, viral particles composed of 
Gagp24 only (no Env) were administered.  All vaccines elicited high-titer serum antibodies that 
recognized the VLP (1:50,000-1:100,000) at week 10 post-vaccination (Fig. 13A).  In addition, 
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anti-VLP IgG antibodies were detected in the lung wash from all mice (Fig. 13B).  Neutralizing 
antibodies were detected in the serum from all vaccinated groups (1:40-1:80).  However, these 
titers were the same as those detected in mice vaccinated with Gagp24 particles. 
 
 
Figure 13 Antibody responses. 
(A) Anti-VLP titers were determined by ELISA with 96-well plates coated with matched VLPs 
at 50 ng per well. Week 10 sera were tested starting at a dilution of 1:200. Endpoint was assigned 
as the dilution at which background was reached. (B) Week 10 lung washes were used to 
determine anti-VLP titers in the mucosa. Washes were tested starting at a dilution of 1:10.  All 
responses are shown as the average titer for each vaccine group plus the standard deviation. 
4.4.3 Elicitation of Cellular Immune Responses. 
Splenocytes from mice vaccinated with either consensus Env VLPs and wild-type Env VLPs 
(monovalent or polyvalent) secreted IFN-ɣ following stimulation with Env specific peptides 
(Fig. 14A and B).   No Env-specific immune responses were elicited in mice vaccinated with the 
Gagp24 particles.  Pools of peptides representing each region of Envgp160 were matched to the 
subtype (i.e. subtype B peptides were used to stimulate cells from subtype B vaccinees).   Anti-
Env splenocyte responses were detected throughout all regions of Env in both clade B (300-800 
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spots per 10
6
 splenocytes) and clade C (100-400 spots per 10
6
 splenocytes). There was no 
statistical difference in the number of spots elicited between consensus Env VLPs and polyvalent 
or monovalent Env VLP vaccines in either subtype.  Interestingly, there were differences in the 
cellular responses elicited in the lung mucosa (site of vaccination) compared to the responses 
detected in the spleen.  All three vaccine strategies (consensus, polyvalent, and monovalent) 
elicited a high number of responses to the V3 region for both subtypes (Fig. 14C and D).  
However, mice vaccinated with Con B VLPs had additional responses to C1, C3, V4-C5, 
ectodomain of gp41 (gp41ecto), the transmembrane (TM) and amino terminal region of the 
intracytoplasmic domain (gp41TM/ICD N’).  In contrast, mice vaccinated with Poly B VLPs had 
significant responses to only gp41TM/ICD N’ and the carboxyl region of the intracytoplasmic 
domain (gp41ICD C’).  The monovalent PVO.4 VLP elicited mucosal responses against V4-C5, 
gp41TM/ICD N’, and gp41ICD C’ regions.  Similar responses were observed using the subtype C VLP 
vaccines (Fig. 14D).   
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Figure 14 Anti-envelope cell-mediated immune responses. 
T cell immune responses induced by consensus, polyvalent and monovalent clades B and C 
vaccines. Splenocytes (A and B) and lung cells (C and D) were isolated and stimulated with 
overlapping clade-matched envelope peptides. Peptides were separated into approximately equal 
sized pools of peptides representing the different regions of envelope. Responses are represented 
as SFU per million cells. The values of each column are the mean ± standard deviation from 
individual animals (n=10). 
 
4.4.4 Envelope Cellular Epitopes 
Individual peptides responsible for eliciting cellular immune responses in each peptide set were 
identified using matrix format peptide pools and then confirmed by testing the peptides 
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individually [254].  Thirty-five individual peptides were identified in mice vaccinated with the 
Con B VLP against the subtype B peptide set and 35 cross-reactive peptides were identified 
against the subtype C peptide set (Fig. 15 and Table 2).  Similar number of peptides was detected 
in mice vaccinated with the Poly B VLPs, however, almost no peptides were identified using the 
monovalent PVO.4 VLP.  Interestingly, at least 15 individual peptides were identified by each 
subtype C VLP vaccinees against both subtype B and subtype C peptide sets.  Mice vaccinated 
with the Poly C had similar number of identified peptides (15 against subtype B peptides and 17 
against subtype C peptides).  The monovalent DU151 VLP vaccinated mice responded to a 
comparable number of peptides as the Poly C against subtype B peptides (20), but to an 
increased number of identified subtype C peptides (32).  Interestingly, mice vaccinated with the 
Con C VLP responded to twice as many individual peptides identified (50) from the subtype B 
peptide set as the subtype C peptide set (23).  
The identified epitopes were mapped to each region of Envgp160 (Fig. 16).  Since both 
subtype B and subtype C peptide contain overlapping peptides, it was important to determine the 
percent of the Env covered by these responses and not just the number of peptides identified.  
The Con B and Poly B VLP vaccines clearly demonstrated increased coverage of both subtype B 
and C peptide sets compared to the monovalent PVO.4 VLP (Fig. 16 and Table 3).  Mice 
vaccinated with the Con B or Poly B VLP vaccines elicited cellular responses that covered 40-
50% of the envelope with equal distribution throughout the protein.  Mice vaccinated with Con C 
VLPs elicited similar coverage as the Con B VLP (~61%) as detected by the subtype B peptide 
set (Fig. 16), however, only half as much of Env was covered when the subtype C peptide set 
was used for analysis, with almost no recognition of the peptides in the Envgp41.   Both the Poly 
C and monovalent DU151 VLP vaccines elicited responses that recognized less of the envelope 
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than the Con C vaccine when tested using the subtype B peptide set.  However the monovalent 
DU151 VLP had more coverage of the Env than Con C or Poly C VLPs when splenocytes were 
stimulated using the subtype C peptide set.  
To determine the subpopulation of T cells elicited by these vaccines, splenocytes were 
depleted of CD4
+
 T lymphocytes.  Less than 10% of the remaining splenocytes were CD4 
positive.  The most reactive common epitopes from both peptide sets were tested against the 
CD4
+
 depleted splenocytes.  This subset of peptides elicited similar numbers of IFN-ɣ producing 
spots to each of the epitopes tested (Fig. 17).  Upon the depletion of CD4
+
 T lymphocytes, all 
immune responses were lost indicating that all epitopes were CD4 restricted. 
 
 
 
 
Figure 15 Identification of envelope-specific peptides. 
Individual envelope peptides were identified by ELISpot using peptide pools in a matrix format. 
Epitopes were considered positive if they were at least two-fold higher than responses observed 
with Gag only vaccinations. Total number of epitopes recognized by each vaccine in both Con B 
and Con C envelope peptide sets. 
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Table 3 Env peptides individually identified by VLP vaccines. 
 
a
 Vaccine group. 
b 
Env peptide set, numbers represent the NIH AIDS Research and Reference Reagent Program 
catalog number for each identified peptide. 
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Figure 16 Env regions covered by elicited Env cell-mediated immune responses. 
Identified epitopes were mapped to the appropriate location within Env for each vaccine group as 
labeled on the left. Epitopes are shown as boxes of the length covered and on the right the 
percentage of Env covered by these epitopes is shown. Con B epitopes are shown in black and 
Con C epitopes are shown in grey. 
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Table 4 Number of peptides identified per region of Env. 
 
a
 vaccine group. 
b 
Env peptide set, number represents the number of peptides identified per region of Envelope 
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Figure 17 Identified epitopes require CD4+ T lymphocytes. 
The most common and reactive epitopes from Con B and Con C envelopes were used to 
determine if the identified epitopes were CD4 or CD8
+
 T cell Responses. Splenocytes were 
isolated and stimulated with individual peptides (8 Con B and 7 Con C) either with or without 
CD4 cell depletion. Responses are represented as SFU per million cells. The values of each 
column are the mean ± standard deviation. 
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Table 5 Percent sequence homology with Env peptide sets. 
 
4.5 DISCUSSION 
The intrinsic diversity among circulating populations of HIV-1 in various geographical locations 
is one of the greatest challenges for developing an effective AIDS vaccine. There is a great need 
to develop vaccines that can elicit enduring protective immunity to variant HIV-1 strains.  While 
variation is observed in all of the viral proteins, the greatest diversity is localized to the viral 
envelope glycoproteins, evidently reflecting the predominant role of these proteins in eliciting 
host immune recognition.  In this study, we examined the effectiveness of two vaccine strategies 
(polyvalent and consensus) for eliciting broadly reactive immune responses against Envs from 
diverse clade B and C isolates.  Virus-like particles were used to deliver these envelopes in a 
native, trimeric structure [255] to a mucosal surface that effectively elicited cellular immune 
responses.  Each VLP vaccine expressed similar amounts of envelope on the particle surface 
(Fig. 12) and therefore differences in the elicited immune responses were due to the particular 
envelope and not the amount of Env antigen delivered. 
 90 
All VLP vaccines were highly immunogenic with each VLP vaccine eliciting neutralizing 
antibodies against a panel of viral isolates.  However, viral Gagp24 particles elicited similar 
neutralizing titers indicating that a majority of the neutralization activity was most likely directed 
to cellular proteins embedded in the viral membrane and were not Env-specific.  Similar results 
were also observed following vaccination with VLPs or inactivated virus in rabbits and guinea 
pigs (our unpublished observations and [256]).  The VLPs used in this study were produced in 
non-human primate cells and therefore the particle membrane was coated with host cellular 
proteins that are foreign to the mouse immune system and thereby elicit strong immune 
responses.  While this may be arguably beneficial for a VLP vaccine, it limited the ability to 
determine the effectiveness of a polyvalent or consensus Env vaccine strategy to elicit broadly 
reactive neutralizing antibodies.  Therefore, future studies in primates, possibly using DNA or 
viral vectors expressing the Envs from a VLP in vivo, will be necessary to answer these 
questions. 
Each VLP vaccine elicited strong anti-Env cell-mediated immune responses as detected 
by both the Con B and Con C Env peptide sets.  These sets were chosen since they represented 
all of clade B and C viruses instead of any single isolate.  The Con B sequence used in the 
peptide set was ~90% identical to the four Envs sequences used in the Poly B Env VLP vaccine 
(Table 5) and they were ~82% identical to the Con C peptide set.  Similar results were observed 
with the clade C isolates to the Con C peptide set.  Both consensus and polyvalent Env vaccine 
strategies elicited cell-mediated immune responses throughout all regions of Env.  However, the 
number of specific epitopes elicited by Con B and Poly B Env VLPs was trended towards higher 
responses than the monovalent clade B Env VLP (Fig. 15).  No matter how potent a response to a 
particular epitope in envelope is, it is not advantageous if the vaccine responses are focused on 
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epitopes that are retained only in a small percentage of HIV-1 isolates [232, 236].  Focusing 
vaccine responses on epitopes that have escaped and are rare in the current population of virus 
isolates may be a disadvantage for an effective vaccine. Con B and Poly B Env VLPs elicited 
responses that recognized 70 and 60 different peptides and covered 48.5% and 44% of the 
envelope, respectfully.  The monovalent clade B Env VLP vaccine induced recognition of only 
three peptides and covered 2.55% of the envelope epitopes.  In contrast, the monovalent DU151 
VLP elicited cell-mediated immune responses as efficiently as Con C or Poly C Env VLPs 
against the Con C peptides.  Interestingly, the Con B and Poly B Env VLP vaccines had greater 
or equal coverage of the Con C envelope than any of the clade C vaccines tested (Fig. 6).  This is 
likely due to the higher reactivity observed with the clade B vaccines than the clade C vaccines.  
However, the Con C Env VLP elicited more cross-reactive responses that covered more clade B 
epitopes than either Poly C or monovalent clade C Env VLP vaccines.   
We were concerned that using consensus peptide sets to compare consensus to polyvalent 
Env vaccine strategies would bias our results towards a consensus Env vaccine strategy.  These 
peptide sets were chosen because they were readily available from the NIH AIDS Reference and 
Reagent Program.  Interestingly, the Con B peptide set was not more likely to detect specific 
epitopes elicited by a Con B Env antigen compared to a mixture of Envs.  In addition, similar 
results were observed using a peptide set derived from the clade B isolate, SF162 (data not 
shown).  This was not surprising, since the SF162 had ~94% identical amino acids as the Con B 
sequence. 
These VLP vaccines were administered intranasally to elicit mucosal immune responses.  
Intranasal immunization with VLPs induced both systemic and mucosal
 
immunity. Mucosal 
infection serves as the major route of HIV infections in the world [257].  While circulating virus 
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and virus-specific immune responses are detected in the periphery shortly after infection, virus-
specific immune responses at mucosal sites are critical for the control of infection in many 
individuals exposed to HIV-1 [258-260].  One advantage of using VLPs, compared to the low or 
undetectable level of immune responses elicited by soluble antigens delivered intranasally [219], 
is the administration of these VLPs, with CpG oligodeoxynucleotides as an adjuvant, enhances 
both systemic and mucosal immune responses [261-266].  This is most likely due to 
phagocytosis of the VLP immunogen by microfold epithelial cells (M cells) in the nasal lumen 
that leads to direct deposition of antigen to the nasal associated lymphoid tissue (NALT) via M 
cell transcytosis [267].  This process results in the induction of strong local (NALT), as well as 
distant immune responses in both peripheral and mucosal immune compartments [268].  
Interestingly, there were differences in the regions of Env recognized by mucosal T cells 
using these vaccines compared to peripheral T cells (Fig. 14).  All the vaccines elicited responses 
against V3 and gp41 regions of Env.  However, the Con B and Con C Env VLPs elicited a 
broader recognition of Env regions in the mucosa than the monovalent or polyvalent Env VLP 
vaccines. The elicitation of a broader mucosal cell-mediated immune response by the consensus 
Envs may allow for recognition of a larger number of isolates at the site of infection.  Future 
studies in non-human primates will be needed to determine if these VLP vaccines, administered 
intranasally, elicit vaginal mucosal immune responses.  Intranasal immunization directly 
stimulates the vaginal mucosal immune system to elicit high titer responses [269-271] and 
therefore, VLP administration may be an effective strategy to elicit genital mucosal responses. 
The aim of this study was to evaluate the breadth of coverage generated by Consensus 
and Polyvalent virus-like particle vaccines.  The breadth of coverage was evaluated using 
consensus B and C envelope peptide sets.  All vaccines were able to generate equal levels of 
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antibody and cellular responses systemically as well as mucosally.  The qualities of these 
responses were not equal.  Both the ConB and ConC VLP vaccines generated responses that 
recognized a greater number of Env epitopes thereby creating a greater coverage of Env than 
either polyvalent vaccine.  These results indicate that a Consensus VLP vaccine would likely 
provide the greatest protection against a wide range of isolates as compared to a polyvalent 
vaccine.   
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5.1 FOREWORD 
This aim was completed in collaboration with the Preston Marx at the Tulane National Primate 
Center.  All NHP manipulations and sample collections were overseen by The Marx Lab 
manager, Meredith Hunter.  ADCVI activity was measured by Donald N. Forthal.  All other 
immune responses were measured by Sean P. McBurney.  The authors would also like to thank 
Hermancia Eugene and Dilhari DeAlmeida for their contribution to purifying VLP for this study.  
5.2 ABSTRACT 
The vast diversity of HIV-1 infections has greatly impeded the development of a 
successful HIV-1/AIDS vaccine.  Previous vaccine work has demonstrated limited levels of 
protection against SHIV/SIV infection, but protection was only observed when the challenge 
virus was directly matched to the vaccine strain.  As it is likely impossible to directly match the 
vaccine strain to all infecting strains in nature, it is necessary to develop an HIV-1 vaccine that 
can protect against a heterologous viral challenge. In this study we investigated the ability of 
polyvalent and consensus vaccines to protect against a heterologous clade B challenge.  Rhesus 
macaques were vaccinated with ConB or PolyB virus-like particle vaccines.  All vaccines were 
highly immunogenic with high titers of antibody found in all vaccinated groups against SIV Gag.  
Antibody responses were also observed against a diverse panel of clade B envelopes.  Following 
vaccination NHPs were challenged via the vaginal route with SHIVSF162p4.  The PolyB vaccine 
induced a 66.7% reduction in the rate of infection as well as causing a two log10 reduction in 
viral burden if infection was not blocked.  ConB vaccination had no effect on either the infection 
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rate or viral burden.  These results indicate that a polyvalent clade matched vaccine is better able 
to protect against a heterologous challenge as compared to a consensus vaccine.   
5.3 INTRODUCTION 
It is estimated that 33 million people worldwide are currently living with HIV-1with 2.7 million 
people becoming newly infected in 2008 highlighting the need for a preventative vaccine [272].  
One of the greatest struggles against developing an HIV-1 vaccine is the large diversity of viral 
isolates with differences in envelope sequences, which differ by as much as 10% within a given 
clade and 35% across clades [273].  Previous vaccine studies in non-human primates 
demonstrated sterilizing immunity, but protection was only observed when the vaccine was 
exactly matched to the challenge strain [223-224, 226, 274-275].  An effective HIV/AIDS 
vaccine will need to protect against heterologous viral challenges. 
Various strategies have been investigated to address the issue of Env diversity (for review 
see [276]).  Polyvalent vaccines have been found to be an effective strategy in the protection 
against a number of infections including Pneumococcus, Influenza, and Polio [105].  Polyvalent 
vaccines are typically composed of multiple copies of a given target(s), thereby increasing the 
diversity of the epitopes presented to the immune system.  If the diversity of the epitopes is large 
enough within the polyvalent vaccine, it can present one or more epitopes present in any given 
isolate.  Polyvalent HIV/AIDS vaccines do increase the breadth and strength of both cellular and 
humoral immune responses compared to monovalent vaccines [107-108, 114-116, 118, 227-228, 
277-278].  
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Another strategy to address the issues of Env diversity is the construction of envelope 
antigens based upon a consensus sequence derived from numerous HIV-1 isolates.  These 
vaccines utilize a consensus sequence that has been artificially generated to represent the most 
common amino acid at each position of a given target from a collection of sequences.  The goal 
of this strategy is to minimize the genetic difference between the vaccine strain and any given 
primary isolate.  Previous studies have indicated that consensus Env proteins are functional and 
highly immunogenic [84-85, 90-94, 277].  Consensus vaccines can induce a broader immune 
response as compared to a primary isolate [277]. 
The first aim of this study was to compare the ability of a consensus clade B (ConB) and 
a polyvalent clade B (PolyB) Env vaccine to develop a broadly reactive immune response in a 
non-human primate model.  Both vaccines were delivered on the surface of a virus-like particle 
to facilitate the presentation of envelope in its native conformation.  The second aim was to 
determine the ability of a consensus and polyvalent vaccine to protect against a SHIV challenge.  
Following vaccination, all non-human primates (NHPs) were challenged with a SHIVSF162p4 via 
the intravaginal route.  SHIVSF162p4was heterologous to both the ConB and PolyB vaccines thus 
better representing a potential transmission event.  The vaginal route was chosen as this is the 
most common transmission route worldwide [279]. This is the first study to directly compare the 
breadth of immunity generated by a consensus and polyvalent vaccine in a non-human primate 
model. 
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5.4 MATERIAL AND METHODS 
5.4.1 DNA Plasmids 
The pTR600 vaccine plasmid [237] and the HIV-1 VLP expressing plasmid, have been 
previously described [238]. Briefly, the pHIV-wtVLPADA plasmid encodes for the following 
gene sequences: HIV-1BH10 gag–pol (pHIVBH10 nt 112–3626) (accession number M1564) and 
HIV-1ADA vpu, env, rev, tat (nt 5101–8159).  Safety mutations were engineered into Gag to 
prevent viral RNA packaging [239-240] and RT to prevent reverse transcriptase and RNase H 
activity (pHIV-VLPADA) [23, 241-242].  A codon optimized SIVMac239 p55 Gag gene (generous 
gift from Dr. Andrea A. Gambotto) was cloned into pTR600 to generate the SIV Gag VLP. Each 
VLP was expressed from a cytomegalovirus immediate-early promoter (CMV-IE) for initiating 
transcription of eukaryotic inserts and the bovine growth hormone polyadenylation signal (BGH 
poly A) for termination of transcription. 
Consensus VLPs were constructed by substituting ADA env with the consensus env 
sequences from the consensus clade B envelopes (LANL database).  These sequences represent 
the most common amino acids found at each location within the Env gene from over 200 isolates 
for each clade.  The primary isolate VLPs were constructed by substituting ADA env with the 
primary env sequence.  These isolates were obtained from the AIDS Reagent and Reference 
Program.  These isolates were chosen as they were isolated from diverse geographic locations 
during the acute phase of HIV infection[183, 253].  All VLPs have been previously shown to 
incorporate similar amounts of envelope [277].   
Each plasmid was amplified in Escherichia coli strain-DH5 alpha, purified using anion-
exchange resin columns (Qiagen, Valencia, CA), and stored at -20
o
C in dH2O. Plasmids were 
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verified by appropriate restriction enzyme digestion and gel electrophoresis. Purity of DNA 
preparations was determined by optical density reading at a wavelength of 260 and 280 nm. 
5.4.2 Purification of virus-like particles 
Supernatants from COS cells, transiently transfected with plasmid expressing Gag or VLPs were 
purified via ultracentrifugation (100,000 X g through 20% glycerol, weight per volume) for 4 h 
at 4
o
C as previously described [255]. The pellets were subsequently resuspended in PBS and 
stored at -20
o
C until use.  Protein concentration was determined by Micro BCA
TM
 Protein Assay 
Reagent Kit (Pierce Biotechnology, Rockford, IL, USA).   
5.4.3 MHC haplotype determination 
MHC haplotyping was completed by the MHC Typing core at the University of Wisconsin AIDS 
Vaccine research laboratory (Madison, WI, USA).  Briefly 2 ml of EDTA anti-coagulated blood 
was collected and sent shipped overnight at 4
o
C.  MHC genotyping was competed using PCR-
SSP typing for A01, A02, A08, A11, B01, B03, B04, B08, and B17 genotypes.   
5.4.4 Immunization of Rhesus macaques 
Rhesus macaques, Macaca mulatta, were anesthetized with ketamine (10mg/kg).  Vaccinations 
were completed at 8 week intervals over 32 weeks.  The first two vaccinations were given as 
DNA vaccinations.  All groups received 1 mg each of DNA encoding the HIV VLP containing 
Env and SIV Gag VLP in 1ml saline via an IM injection.  All groups received 4 µg of HIV VLP 
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and SIV VLP plasmids via gene gun (Bio-Rad, Hercules, CA, USA) over the inguinal lymph 
nodes.  The third and fourth vaccinations were administered as 250 µg each of purified HIV VLP 
and SIV VLP with CpGs, 125 µg.  The vaccines were split with 125 µg given via an 
intramuscular injection in the quadriceps and the second 125 µg given via the intranasal route. 
Each CpG ODN: K3- ATCGACTCTCGAGCGTTCTC, D35- 
GGTGCATCGATGCAGGGGGG, K123- TCGTTCGTTCTC, D29- 
GGTGCACCGGTGCAGGGGGG, D19- GGTGCATCGATGCAGGGGGG [280] was 
synthesized and purified by high-pressure liquid
 
chromatography (Sigma-Genosys, The 
Woodlands, TX, USA).  The
 
CpG ODNs were resuspended in sterile dH2O (2 g/µl) and stored 
at -20C.   
5.4.5 Intravaginal Challenge 
All animals were challenged intravaginally with SHIVSF162p4 which was obtained from Drs. 
Nancy Miller (DAIDS, NIAID) and Dr. Ranajit Pal (ABL, Kensington, MD, USA).  Briefly all 
animals were anesthetized using an intramuscular injection of either Ketamine or Telazol before 
virus exposures.  All virus exposures were a 1 ml dose of 640 TCID50 with the animal in the 
supine position which was maintained for at least ten minutes.  Viral exposures were completed 
on days 0, 3, 7, and 10.     
5.4.6 Collection of Samples 
Animals were anesthetized using an intramuscular injection of either Ketamine (10mg/kg) or 
Telazol (0.1ml/kg).  Blood was collected from the femoral vein using the Sarstedt Monovette 
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blood collection system (Sarstedt, Inc., Newton, NC, USA).  PBMCs were collected and purified 
using ACCUSPIN
™
 System-Histopaque
®
-1077 tubes according to the manufactures instructions 
(Sigma-Aldrich, St. Louis, MO, USA).  Vaginal washes were collected following anesthetization 
with Telazol.  The vaginal mucosa was washed with 5 ml of sterile PBS.  Samples were collected 
and centrifuged to separate cells and supernatants at 3000 rpm for 10 min.  Cells and supernatant 
were taken separately and stored at -80
o
C until used. 
5.4.7 Viral load Determination 
Viral RNA (vRNA) levels were determined by Siemens Diagnostics Clinical Laboratory using 
the SIV RNA 4.0 bDNA Assay (Siemens Diagnostics, Berkeley, CA, USA).  Plasma samples, 
0.5 ml, were collected as stated above and sent to Siemens for processing.  Briefly Plasma was 
concentrated via centrifugation.  The SIV genomic RNA is then captured to a microwell by 
probes targeted to the pol gene.  The pre-amplifier probes are then added binding to the vRNA.  
Amplifier probes are then added forming a branched DNA (bDNA) complex.  Substrate is added 
resulting in light emission which is directly proportional to the amount of vRNA present in the 
sample.  A standard curve is used to determine the concentration of vRNA per sample.   
5.4.8 CD4/CD8 Cell count 
EDTA-treated whole blood was stained using CD3, CD4 and CD8 monoclonal antibodies 
and analyzed using a BD FACSCalibur Flow Cytometer (BD Biosciences, San Jose, CA, USA).  
Cell counts were determined using the BD Truecount tubes according to the manufacture’s 
instructions (BD Biosciences, San Jose, CA, USA). 
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5.4.9 CD8+ lymphocyte depletion 
Rhesus macaques were treated with the antibody cM-T807 (Nonhuman Primate Reagent 
Resource, Boston, MA, USA).  This treatment was started at day 160 post-infection.  Antibody 
was given on day 0 post-infection at a dose of 10mg/kg given subcutaneously.  Additional doses 
were given at days, 3, 7, and 10 at a dose of 5 mg/kg given via the intravenous route.  
Intravenous treatments were given as a slow bolus over 10-20 minutes.  CD8 depletion was 
confirmed by flow-cytometry.    
5.4.10 Antibody Responses to VLP immunization 
Serum and mucosal wash samples were individually collected and tested for antibody 
(IgG) responses to SIV Gag and multiple gp120 isolates by ELISA.  For the Env ELISAs each 
well of a 96-well plate was pretreated with 5 µg of concanavalin A (Con A)for 1 hr at 25
o
C.  For 
all ELISAs each well of a 96-well plate was coated with 50 ng per well of the respective protein 
(4°C for 16 hr).  Plates were blocked (25°C for 2 hr) with PBS containing Tween 20 (0.05%) and 
nonfat dry milk (5%) and then incubated with serial dilutions of each sample (25C for 2 hr).  
Following thorough washing in PBS-Tween 20 (0.05%), samples were incubated (25°C for 1 hr) 
with biotinylated goat anti-mouse IgG conjugated to horseradish peroxidase (HRP) diluted 
1:5000 in PBS-Tween 20 (0.05%) and nonfat dry milk (5%).  The unbound antibody was 
removed, and the wells were washed.  Samples were incubated with TMB substrate (1 hr), and 
the colorimetric change was measured as the optical density (O.D., 405nm) by a 
spectrophotometer (BioTek Instruments, Winooski, VT, USA).  The O.D. value of naïve sera 
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was subtracted from the samples using antisera from vaccinated mice.  Results were recorded as 
the arithmetic mean ± the standard deviation.  
5.4.11 Neutralization Assay 
Antisera were tested for the ability to neutralize virus infection in vitro using TZM-Bl 
cells indicator cells [251-252].  These cells express human CD4 (hCD4), human CCR5 (hCCR5), 
human CXCR4 (hCXCR4), and a luciferase reporter driven by the HIV-1 LTR. TZM-Bl cells 
were cultured in cDMEM with 10% fetal calf serum (10%) (Atlanta Biologicals, Atlanta, GA, 
USA).  Infectivity was determined using serial dilutions of antisera with cells in complete, non-
selective media in the presence of DEAE dextran (20 g/ml) (25°C for 1hr).  Cell lysates were 
harvested in lysis buffer (25mM Tris phosphate, pH=7.8, 2mM DTT, 2mM 1-2-
diaminocyclohexane-N, N, N’, N’-tetraacetic acid, 10% 103lycerol, 1% Triton X-100) (48 h) and 
then clarified by centrifugation.  Virus neutralization by antisera was determined by measuring 
the relative light units (RLU) using an Orion Microplate Luminometer (Berthold Detection 
Systems, Pforzheim, Germany).   
 
5.4.12 ELISpot Assays 
The number of anti-Gag and anti-Env specific nonhuman primate IFN- (mIFN-) 
secreting splenocytes was determined by enzyme-linked
 
immunospot (ELISPOT) assay (R & D 
Systems, Minneapolis, MN, USA).  Briefly, pre-coated anti-IFN- plates were incubated (25°C 
for 2 h) with cRPMI (200 µl) and then were incubated with PBMCs (2.5 X 10
5
/well).  PBMCs 
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were stimulated (48 h) with peptides (15mers overlapping by 11 amino acids) representing the 
SIVMac239 Gag or SF162 Env proteins (NIH ARRRP). Control wells were stimulated with 
PMA(+) (50 ng)/ionomycin (500 ng) or were mock stimulated (-).  Plates were washed with 
PBS-Tween (3X) and were incubated (37°C for 24 h; 5% CO2) with biotinylated anti-mIFN- 
and incubated (4C for 16 h).  The plates were washed and incubated (25°C for 2 h) with 
streptavidin conjugated to alkaline phosphatase.  Following extensive washing, 
cytokine/antibody complexes were incubated (25°C for 1 h) with stable BCIP/NBT chromagen.  
The plates were rinsed with dH2O and air dried (25°C for 2 h).  Spots were counted by an 
ImmunoSpot ELISpot reader (Cellular Technology Ltd., Cleveland, OH, USA). 
5.4.13 Antibody-dependent cell mediated virus inhibition 
Antibody-dependent cell-mediated viral inhibition (ADCVI) antibody
 
activity was measured 
using methods similar to those described
 
previously [149]. Briefly, target cells (CEM.NKR-
CCR5 cells
 
infected with SHIVSF162p4 virus for 48 h) were incubated with serum and with
 
fresh 
human PBMC effector cells (effector/target ratio = 10:1).
 
Seven days later, p27 from the 
supernatant was determined by
 
ELISA (Zeptometrix Corporation, Buffalo, NY). 
5.4.14 Statistical analysis 
Anti-SIV Gag antibody responses, viral peak, viral burden and anti-SF162 Env antibody 
responses were compared pair wise using a one sided student’s t test.  The breadth of envelope 
binding was analyzed using a One-way ANOVA test along with Tukey’s multiple comparisons 
secondary test.    
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5.5 RESULTS 
5.5.1 Vaccines 
The goal of this study was to enhance the breadth of immune responses directed against 
HIV-1 envelope.  To achieve this goal, a mixture of wild-type (polyvalent) or consensus 
envelopes were used as immunogens on the surface of a virus-like particle (VLP).  These 
vaccines were measured by determining their ability to elicit broadly reactive immune responses 
and to protect against a heterologous infection.  A consensus clade B (ConB) and a polyvalent B 
(PolyB) VLP vaccine were based on an identical virus-like particle background with the only 
difference being the envelopes expressed on the surface (Table 6).  As previously described 
[277], the consensus Env sequences were generated by selecting the most common amino acid at 
each position of a full-length Env alignment derived from 200 subtype B viruses deposited in the 
Los Alamos HIV Sequence Database.  Each set of subtype sequences was supplemented with 
env sequences used in a standardized neutralizing panel [183] 
The PolyB vaccine is composed of four separate VLPs with each expressing an 
individual Env isolate.  These isolates were selected for their genetic, geographic, and 
transmission diversity.  In addition, isolates were chosen only if they were isolated within a few 
weeks after transmission, since these early isolates may represent the majority of mucosally 
transmitted HIV isolates [281].  Vaccinations were administered systemically (intramuscular 
injection) and mucosally (intranasal delivery) to generate both mucosal and systemic immune 
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responses.  Each non-human primate (NHP) was identified by a color-code within each given 
study group to facilitate easy comparisons between immune responses and infection outcome 
(Table 7).  
Table 6 Virus-like Particle Vaccines 
 
Table 7 Individual NHP Coding 
 
Each NHP per group was identified by a particular color to facilitate the following of pre-challenge 
immune responses against infection outcomes.  Each NHP is was also given a unique code for 
further identification. 
5.5.2 Immune Responses to VLP vaccination 
Cellular immune responses were investigated against both SIV Gagp55 (mac239) and 
HIV-1 Envgp160 (SF162).  Positive cellular responses were not detected either systemically 
(peripheral blood draw) or mucosally (intestinal lymph node biopsy) from any of the vaccine 
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groups (data not shown).  However, both  ConB and PolyB VLP vaccines elicited strong SIV 
Gagp55 antibody responses with a trend towards higher antibody responses induced by the PolyB 
VLP group compared to the ConB VLP vaccine group (p=0.0676) (Fig. 18).  Limited SIV Gag 
antibody responses were also detected in vaginal wash samples (Fig. 18).   
 
 
Figure 18 Systemic and mucosal antibody responses are generated by both vaccines. 
Serum samples and vaginal washes were taken two weeks following the completion of the 
vaccine regimen.  Individual serum samples (A) and vaginal washes (B) were tested via serial 
dilution against SIV Gag p55. * Indicates p-value <0.05, Statistics were completed using 
Student’s T-test. 
 
5.5.2.1 Breadth of anti-Env antibody responses  
The primary goal of this study was to increase the breadth of viral isolates recognized.  
This was measured via Env binding ELISAs and Neutralization assay utilizing a panel of diverse 
Envelopes.  First envelope antibody-binding titers against homologous Envelopes were 
determined (Fig. 19a).  Against the ConB Env, only two of four NHPs from the ConB and the 
PolyB VLP group demonstrated recognition.  Against the envelopes from the PolyB VLP 
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vaccine, The PolyB group recognized all isolates with at least two of four responding.  Within 
the ConB VLP group, only PVO.4 was recognized by BK31.  Next a panel of heterologous 
envelopes was tested (Fig. 19B).  These envelopes were selected, as they were isolated early 
during infection and are hypothesized to be more representative of transmitting virus than late-
stage isolates[183, 253].  Against these envelopes, only the PolyB VLP group demonstrated 
antibody binding to all isolates with at least one NHP recognizing all of the isolates tested.  The 
ConB VLP group only demonstrated antibody binding against two of the envelopes, and each 
time only one NHP facilitated the recognition.  The PolyB VLP group demonstrated a 
significantly greater breadth of anti-Env antibody responses than either the unvaccinated or 
ConB VLP groups (Tukey’s multiple comparison test).  Of particular interest was the response to 
the SF162 envelope, since this strain matches the challenge virus.  Antiserum from one out of 
four NHPs from the ConB VLP group recognized the SF162 Envgp120, while the serum from 2 
out of 4 of the NHPs from the PolyB VLP group recognized the SF162 envelope (Fig. 20).  
Mucosal antibody responses, neutralizing antibodies and antibody-dependent cellular virus 
inhibition (ADCVI) were not detected against any of the envelopes tested (data not shown).   
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B. 
 
 
Figure 19 Breadth of pre-challenge anti-Env antibody responses. 
Serum samples obtained two weeks following the final vaccination were tested via serial dilution 
against homologous (A) and heterologous (B) Env isolates.  Results are represented as the 
average response from the four NHPs per group minus background responses observed in pre-
vaccination samples.     
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Figure 20 Anti-SF162 Envelope antibody responses. 
Serum samples obtained two weeks following the final vaccination were tested via serial dilution 
against SF162 envelope.    
5.5.3 Heterologous vaginal SHIV Challenge   
Vaccinated NHPs (n=4) were challenged vaginally (4X) with SHIVSF162p4 (640 TCID50) 8 
weeks following the final vaccination [274, 282].  The envelope in this SHIV is not homologous 
to any of the envelopes used in the VLP vaccine formulation.  The SHIVSF162p4 envelope has a 
~86% amino acid homology with the four primary envelopes used in the PolyB VLP vaccine and 
a 91.3% homology with the ConB Env (Table 8).  Seventy-five percent of unvaccinated control 
NHPs were infected with peak viral loads between 4.3 x 10
6
 and 1.1 x 10
8
 vRNA copies/ml (Fig. 
21A).   When normalized for initial day of infection, the peak viremia was observed at ~14 days 
post-infection.  Normalization was necessary since infections could occur on either day 0, 3, 7, 
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or 10 depending on the viral exposure which established the infection.  Similar results were 
observed with NHPs vaccinated with ConB VLPs who had peak viral titers between 5.4 x 10
5
 
and 2.6 x 10
7
 vRNA copies/ml (Fig. 21C).  In contrast, only one NHP (AH69) vaccinated with 
the PolyB VLP vaccine had detectable virus at any point during the infection period (Fig. 21E).  
The virus titer peaked in this animal at 1.4 x 10
5
 vRNA copies/ml at day 14 post-infection, but 
returned to undetectable levels (>165 vRNA copies/ml) between days 54-70 post-infection. 
CD4
+
 lymphocyte levels were not significantly changed during the course of the infection (Fig 
21B, D, & E).  The total viral burden observed throughout the observation period was measured 
by determining the area-under-the-curve of the viral load (Fig. 22).  The infection status of all 
non-infected NHPs did not correlate with any previously described protective MHC alleles [283-
284] (Table 9). 
 
Table 8 Envelope Sequence Homology 
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Table 9 MHC Alleles 
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Figure 21 PolyB vaccination induced a reduction of viral load following heterologous 
challenge. 
Viral RNA copies/ml in plasma samples and CD4
+
 lymphocyte counts: (A, B) Naïve, (C,D) 
ConB, and (D,E) PolyB  
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Figure 22 PolyB vaccination induced a reduction of viral burden following heterologous 
challenge. 
Viral burden of infection measured by the area-under-the-curve of each individual viral load 
from day 0 to day 168 post-infection. 
5.5.4 CD8+ lymphocyte depletion 
All non-infected and infected NHPs who had undetectable virus at day 188 post-infection 
were depleted of CD8 T cells to release low viral titers in reservoir tissues.  All NHPs were CD8-
depleted via cM-T807 antibody treatment over 10 days.  Complete depletion of CD8+ T cells in 
the blood was confirmed by flow cytometry in all treated NHPs (Fig. 23).  All infected NHPs 
had a rebound virus detected in the blood by day 10 post-treatment (Fig. 23).  All non-infected 
NHPs remained virus free through day 42 post-treatment, further confirming their non-infected 
status (Fig. 23).     
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Figure 23 CD8+ lymphocyte depletion leads to expansion of viral load. 
Viral RNA copies/ml in plasma samples and CD8
+
 lymphocyte counts: (A, B) Naïve, (C, D) 
ConB VLP vaccinated, and (E,F) PolyB VLP vaccinated.   
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5.5.5 Post-Challenge Immune Responses 
Following challenge, there was a marked increase in antibodies to the SF162 Env in all 
infected NHPs, but not in NHPs without detectable virus.  Throughout the post-challenge 
observation period, all non-infected NHPs had unchanged immune responses.  As to not 
artificially decrease the levels of immune responses observed post-infection, all non-infected 
NHPs were not included in average antibody or neutralization titers.  All NHPs were tested for 
all immune responses regardless of infection status.  There was an initial increase in anti-Env 
antibody at day 21 that plateaued by day 54 post-infection and the level of anti-Env antibody 
achieved at day 84 post-infection correlated with viral burden (Fig. 24A & 24B).  At day 42, low 
levels of neutralizing antibodies against the HIV-1 strain, SF162, were also detected.  
Neutralizing antibody levels continued to increase to day 56 and then were maintained through 
day 84 post-infection (Fig. 24B).  ADCVI activity was also detected by day 84 post-infection 
(Fig. 24D).  The kinetics of acquiring antibody responses were similar between all infected 
vaccinated and unvaccinated NHPs.  The effect of vaccination on the breadth of anti-Env 
antibody responses post-infection was also investigated using a panel of envelopes.  All groups 
demonstrated an increase in antibody binding breadth at day 84 post-infection as compared to 
pre-infection (Fig. 25 and 19).  These responses were dependent on the establishment of 
infection with all anti-Env antibody responses being positively correlated to viral burden.  While 
increased binding antibodies were observed, neutralizing antibodies were not detected to any 
envelopes tested excepted to SF162.  There were no cellular responses detected against the 
SF162 envelope at any point during the challenge.  In contrast, SIV Gag cellular responses were 
detected in all infected NHPs to similar levels (Fig. 26). 
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Figure 24 Viral Infection leads to the expansion of binding and neutralizing antibodies 
directed to SF162 Envelope. 
Individual serum samples were tested for binding to SF162 envelope (A) as well as 
neutralization against SF162 pseudovirus (C).  (B) Correlation of viral burden to SF162 end-
point titer was completed by plotting day 84 end-point titer of infected NHPs against their 
respective viral burdens.  Linear analysis was completed to determine line of best fit. (D) 
ADCVI activity against SHIVSF162p4 at day 84 post-infection.     
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Figure 25 Post-Infection breadth of anti-Env antibody responses. 
Serum samples obtained at day 84 post-infection were tested via serial dilution against Envs 
homologous and heterologous to the vaccines tested.  Results are represented as the average 
response from only the NHPs who were infected.  All non-infected NHPs were not included as 
their immune responses remained unchanged post-challenge.   
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Figure 26 Infection leads to the development of anti-SIV Gag cellular Responses. 
PBMCs were tested against an SIVMac239 Gag peptide pools at day 56 post-infection.  Results are 
shown as individual responses with the average response per group shown.   
5.6 DISCUSSION 
The vast diversity of HIV-1 particularly within env has greatly impeded the development of an 
HIV-1 vaccine, and it appears necessary to develop a vaccine that addresses this sequence 
diversity.  In this study, we directly compared two strategies for developing broadly reactive 
vaccines: consensus and polyvalent.  These vaccines were clade B specific with the intent to 
develop a vaccine that can protect against inter-clade isolates and then expand that strategy to 
address all of group M.  Virus-like particles (VLPs) were used as the delivery mechanism for the 
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ConB and PolyB envelopes.  VLPs present envelopes in their native, trimeric structure and also 
facilitate immune responses to the Gag core [255].   These VLPs incorporate similar amounts of 
envelope on their surface so any differences in the immune responses generated are due to 
immunogenic differences and not antigen dosage [277].   
Both vaccines were immunogenic with the majority of recipients developing high 
antibody titers against SIV Gag with both ConB VLP and PolyB VLP vaccines eliciting immune 
responses statistically above naïve levels (Fig. 18).  The PolyB VLP vaccinated NHPs also 
trended to have stronger anti-Gag antibody responses than ConB VLP vaccinees (p=0.0676) 
(Fig. 18).  Interestingly these results indicate that the envelopes on the surface of the VLP affect 
the immunogenicity of the Gag core as both the ConB VLP and PolyB VLP vaccines were 
identical.  It is currently unclear as to the mechanism of this enhancement, but it is likely linked 
to the immunogenicity of the envelopes themselves.   
The goal of the ConB VLP and PolyB VLP vaccines was to induce a broadly reactive 
immune response.  To measure the breadth of immunity, a panel of clade B isolates was selected 
that represent a general sample of all clade B isolates.  Of particular interest were the isolates that 
were identified soon after infection, since these isolates are more representative of sexually 
transmitted viruses, which cause the majority of infections worldwide [183, 279, 281].  
Statistically significant differences were not found between the ConB VLP and PolyB VLP 
vaccines for any given single isolate (Fig. 19).  There was a trend towards higher responses with 
the PolyB VLP vaccine particularly against the early isolates.  The PolyB VLP vaccine did 
induce a statistically significant increase in the breadth of envelope reactivity as measured by the 
Tukey’s multiple comparison test.  This statistical test takes into account the number of 
envelopes recognized as well as the strength of that recognition[91].  It is likely that this 
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increased breadth is due to the presentation of a more diverse set of epitopes as compared to the 
consensus vaccine.  A consensus vaccine will present epitopes that are common to a large 
number of isolates, but it is possible that a polyvalent vaccine will present these common 
epitopes while also presenting a number of unique epitopes.  These unique epitopes would then 
extend the breadth of Env recognition to include isolates that do not contain the most common 
epitopes, but do contain the unique epitopes.  
The true test of any vaccine is its ability to protect against infection.  To determine the 
protective effect of ConB VLP and PolyB VLP vaccines, all groups were challenged with 
multiple vaginal exposures to SHIVSF162p4.  This virus is heterologous to the ConB envelope and 
each envelope in the PolyB vaccine (Table 8).  A vaginal challenge with SHIVSF162p4 with a total 
of four exposures resulted in a 75% infection rate in the Naïve group giving the baseline of 
comparison (Fig. 21).  ConB VLP vaccination had no affect on infection outcome with 75% of 
the group becoming infected.  Two of the infected NHPs had identical viral burdens as compared 
to the naïve group indicating a lack of protective effect.  One NHP in the ConB VLP group did 
demonstrate a one log10 reduction in viral load.  This individual also demonstrated the highest 
anti-Gag antibody responses as well as the only anti-SF162 Env antibody responses in the ConB 
VLP group (Fig. 18 and 20).  It is likely that these immune responses are the reason for the lower 
viral burden.  The PolyB VLP vaccine demonstrated a clear protective effect by reducing the 
infection rate to 25% (Fig. 21).  The one NHP who did become infected demonstrated a 2-log10 
reduction in viral burden over the course of infection indicating that the PolyB VLP vaccine was 
able to reduce the infection if not completely blocked.  It is likely that the high levels of anti-Gag 
and anti-SF162 Env antibody levels induced by the PolyB VLP vaccine were able to induce this 
protection (Fig. 18 and 20).  It is possible that the incomplete protection demonstrated by AH69 
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is due to its lack of anti-Env responses.  AH69 had no detectable anti-SF162 antibody responses 
(Fig. 20) and was the only member of the PolyB VLP group to not recognize any of the 
envelopes tested (Fig. 19) thus limiting its immune protection to anti-Gag antibodies only.  
Previous studies have demonstrated that non-neutralizing antibodies are capable of inhibiting 
HIV-1 infection and replication in macrophages and immature dendritic cells[75].  These cells 
are the first cells exposed to the virus during mucosal transmission and play key roles in the early 
establishment of infection [285-286].  By blocking infection and transmission to these cells the 
PolyB vaccine is able to either completely block infection or significantly reduce the inoculating 
dose.    
Upon the establishment of infection, all groups had similar immune responses.  The rate 
and strength of these immune responses was identical across all groups and was only observed in 
those NHPs that had measurable vRNA levels (Fig. 24, 25 and 26).  This indicates that these 
immune responses were generated in response to the infection alone and were not primed or 
affected by the vaccination state of the NHP.  All post-challenge immune responses also 
correlated with viral burden throughout the disease course further indicating that they were 
dependent on the infection alone (Fig. 24).  These results indicate that vaccination with either the 
ConB VLP or PolyB VLP vaccine did not affect post-challenge immune responses. 
The use of a polyvalent vaccine demonstrated an increased ability to protect against a 
heterologous viral challenge as compared to a consensus vaccine.  This is likely due to the 
increased levels of anti-Gag and anti-SF162 Env antibody responses that were generated.  Future 
work is needed to induce stronger anti-Env immune responses pre-challenge.  The virus-like 
particle platform is limited in the amount of Env on its surface.  It is likely that priming the 
immune response by vaccinating with an Env only vaccine followed by boosting with a VLP will 
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facilitate the generation of a stronger anti-Env responses that may be enriched for neutralizing 
antibodies[274].  The current vaccine strategy also does not induce a cellular response (data not 
shown).  Cellular immune responses may not block the initial infection, but they are capable of 
clearing already infected cells likely further decreasing the viral burden.  To accomplish this 
either a larger dose of purified VLP or a viral-vector delivered VLP is needed[287].  The PolyB 
VLP vaccine used in this study demonstrates that a polyvalent vaccine is the best strategy to 
generate a broadly reactive immune response and that this immune response is capable of 
eliciting protection against a heterologous mucosal SHIV challenge. 
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6.0  SUMMARY AND DISCUSSION 
There is a great need for the development of an effective HIV-1 vaccine.  Each year, 3-4 million 
people are newly infected with HIV-1.  Previous vaccine studies indicated that protection against 
infection is possible in the non-human primate model.  None of these vaccines however have 
resulted in human protection.  A large factor in this lack of protection is the impossibility to 
match the vaccine strain to the range of viral isolates that a person may be exposed.  In most 
protective NHP trials, the vaccine strain and challenge strain have been exactly matched.  
Therefore, it is necessary to develop a vaccine that can induce the protective effect of a matched 
vaccine without being matched to the challenge virus.   
 The overall aim of this dissertation was to determine the best strategy for developing a 
broadly reactive immune response to HIV-1 envelope.  Envelope was the primary target for this 
development as previous work has shown that antibodies directed towards envelope are capable 
of blocking infection if present at the site of infection in sufficient quantities.  The first aim of 
this study was to determine the optimal form of envelope to use in a vaccination.  The second 
aim was to compare the breadth of cellular immunity generated by consensus and polyvalent 
vaccines utilizing the delivery strategy found in aim 1.  The third aim was to compare the breadth 
of humoral immunity generated by consensus and polyvalent vaccines and to determine their 
protective effect against a heterologous mucosal challenge.  This work together has determined 
an optimal strategy for developing a broadly reactive HIV-1 vaccine. 
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 The above work resulted in the development of a polyvalent clade B virus-like particle 
vaccine that is able to induce humoral immune responses that recognize a greater number of viral 
isolates as well as reduce the transmission rate of a heterologous challenge virus.  The PolyB 
vaccine induced both SIV Gag and Env-binding antibody responses.  While anti-VLP antibody 
responses that recognized cellular components of the VLP were generated, it is unlikely that 
these responses had any added effect on preventing infection beyond the immunity induced to 
Env.  These components would have been identical between the ConB and PolyB VLP vaccines.  
However, the ConB VLP vaccine did not demonstrate any protective effect in the absence of 
anti-Env antibody responses.  This indicates that the observed protection was most likely 
dependent on anti-Env antibody binding.  It appears that these antibodies are binding to the virus 
upon viral exposure and blocking the virus’s interaction with dendritic cells and monocytes 
thereby blocking the initial steps of infection.  This reaction appears to be sufficient to 
completely block the infection as indicated by the lack of detectable viral RNA throughout 
infection and the fact that anti-viral immune responses are not boosted or generated after viral 
exposure.  If the immune responses are not at a high enough titer however, this block can be 
overcome as demonstrated by AH69 within the PolyB group.  AH69 had strong anti-Gag 
immune responses, but no detectable anti-Env responses.  The lowered vRNA levels found 
within this NHP, indicate that the initial infection was only partially blocked.  This partial block 
was able to reduce the infecting bolus of virus, but enough virus was able to gain access to 
induce a low level infection.     
 The most recent human HIV-1 vaccine trial is the first to indicate that a HIV-1 vaccine 
can induce a reduction in the rate of infection in humans[288].  This study utilized a vaccine 
containing three different Env isolates.  A single Env, clade B, isolate as well as clade B Gag and 
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Pr were delivered via a canarypox vector followed by boosting with a two separate soluble 
gp120s, clade B and clade E.  This vaccine resulted in a 31.2% reduction in the rate of infection.  
While this vaccine does contain multiple envelopes, which would facilitate increased antibody 
breadth, these envelopes were not specifically selected to generate broad coverage of the HIV-1 
isolates found within Thailand thus potentially limiting the breadth generated.  The use of more 
isolates would likely increase the protective effect observed by Thai vaccine by facilitating 
recognition of a greater number of viruses.  This vaccine does indicate that immune responses 
directed to HIV-1 Env, Gag, and Pr are sufficient to induce protection in humans.  These results 
support the further development of the PolyB VLP vaccine.  The PolyB VLP vaccine induces 
immune responses to both HIV-1 Env and Gag.  The use of the multiple envelopes also increases 
the breadth of the viral isolates recognized thus increasing the number of virus that would be 
protected against.      
 The PolyB VLP vaccine was able to induce immune responses which recognized a 
greater breadth of Env isolates and to induce protection against a heterologous viral challenge.  
One member of the PolyB VLP group was not protected.  This NHP had the lowest immune 
responses observed for the group indicating that stronger induction of immune responses may 
generate greater levels of protection.  In the mouse model, VLP vaccination induces strong 
cellular and humoral immune responses, but in the NHP model, only antibody responses to Gag 
and Env are generated.  These responses remain strong for Gag, but anti-Env responses are only 
observed at moderate to low levels.  It is likely that the differences seen between the two models 
are related to the dose of antigen delivered.  In the mouse model, 40 µg of total VLP is delivered 
corresponding to approximately 1 µg of Env.  In the NHP model, 250 µg of total VLP is 
delivered corresponding to approximately 6 µg of Env.  The 200+ µg dose of Gag appears to be 
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sufficient for inducing strong antibody responses, but the 6 µg of Env appears to be below this 
level.  The dosage of Env is capable of inducing low level antibody responses.  To overcome this 
limited immune response, higher doses of VLP could be used.  It would be beneficial to test 
increasing doses of VLP up to 1 mg per vaccination to determine if the limited anti-Env response 
could be improved.  If a 1 mg dose is still low other methods would need to be explored as 
production limitations would greatly impede doses of greater than 1 mg.   
 One method of increasing the level of anti-Env antibodies generated would be to prime 
with a soluble Env followed by a VLP boost.  Priming with a soluble Env would greatly increase 
the dose of Env delivered allowing for the establishment of high levels of anti-Env antibody 
responses.  Previous studies have shown that strong antibody responses to Env can be generated 
in the NHP model through the use of purified protein, DNA vaccination or viral vectors.  
Boosting with the VLP will further enhance the antibody response.  The boosting effect would be 
most dramatic for those antibodies which recognize Env on the surface of a viral particle.  This is 
of particular importance because these antibodies are the ones that would be the most likely to 
bind Env on the surface of the virus upon infection.   
 Increases in the level and functionality of antibodies to Env and Gag would greatly 
enhance the protective effect of the polyvalent VLP vaccine.  This enhancement would be due to 
increasing the antibody levels capable of blocking HIV-1 infection.  If the initial infection is not 
blocked however it is likely that the vaccine will have no effect on the immune responses post-
infection and they will not increase the rate of viral clearance similar to that seen in aim 3.  The 
induction of cellular immune responses is needed to affect viral clearance upon infection.  
Vaccination with a viral vector has been shown to induce strong cellular immune responses.  
Modified Vaccinia Ankara (MVA) and canary pox vectors have been shown to induce strong 
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cellular immune responses to both Gag and Env.  Both of these vectors would allow for the 
incorporation of the entire VLP expression cassette thus still facilitating correct viral processing 
of the VLP.  The use of a polyvalent vaccine utilizing an Env prime followed by a viral vector 
boost encoding the VLP would induce both strong and broad humoral and cellular immunity 
generating the optimal conditions to block and clear a potential infection. 
 The vaccines studied in this dissertation were all given with CpG adjuvants.  These 
adjuvants have been well established in mouse studies, but they have not been thoroughly 
studied in non-human primates.  It is possible that another strategy of increasing the anti-Env 
antibody responses would be to use a different adjuvant.  A small pilot study conducted in our 
laboratory indicates that using Imject Alum (Thermo Fisher Scientific, Rockford, IL) as an 
adjuvant with these VLP vaccines is able to induce stronger anti-Gag and anti-Env antibody 
responses.  Therefore in future studies, Alum would be a better choice as adjuvant. 
The use of a polyvalent vaccine is the best strategy to induce a broadly reactive immune 
response when measured within a single clade.  It is not clear however if this strategy is capable 
of inducing cross-clade protection.  Once an optimal vaccination regimen has been found, it 
would be beneficial to test a polyvalent vaccine against cross-clade challenge viruses to 
determine the range of protection.  It is possible that a clade-based polyvalent vaccine will likely 
be limited in its cross-clade protection.  This is due to the fact that the polyvalent vaccines are 
designed to address the diversity with the given target set.  If designed for a specific clade, the 
diversity of that clade will be addressed, but the higher level of diversity found across clades 
would be unaccounted for. The design of a polyvalent vaccine to cover multiple clades would 
need to include isolates from all clades of interest.  Computational modeling could be used to 
select isolates that in combination would give the greatest range of coverage.  It is possible that 
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the number of isolates needed to generate sufficient coverage would be too great for use in a 
single vaccine.  Multiple clade specific vaccines could be generated and given according to the 
specific clades prevalent in a given geographic area.   
 One of the greatest challenges with any vaccine is production and distribution.  The 
release of the Human Papillomavirus (HPV) virus-like particle vaccines indicates that a virus-
like particle-based vaccine can be produced in sufficient quantities and purified to a high 
standard for world-wide distribution.  The two HPV vaccines, Gardasil
®
 (Merck & Co. Inc. 
Whitehouse Station, NJ, USA) and Cervarix™ (GlaxoSmithKline Biologicals, Rixensart, 
Belgium), are produced using two separate expression systems.   Cervarix™ utilizes a 
baculovirus expression system which requires multiple chromatographic and filtration techniques 
[289].   Gardasil
®  
is produced using a yeast expression system in which the VLP is expressed by 
a recombinant Sccharomyces pombe vector [290].  Both of these systems produce high quanitites 
of VLPs that are purified through multiple step processes before they are pure enough for human 
use.  HIV-1 VLPs could be produced and purified using similar techniques.  These vaccines are 
and would be highly expensive.  However these costs are much lower than potential anti-
retroviral drug treatments.  It is likely that for an HIV-1 VLP vaccine to be distributed to 
economically depressed areas where it is most needed, governmental or charitable support would 
be needed.     
The development of an HIV-1/AIDS vaccine requires that the vast viral diversity of HIV-
1 isolates be addressed.  The goal of this work was to determine an optimal strategy for 
developing such a vaccine.  The results indicate that a polyvalent vaccine is better capable of 
inducing a broadly reactive immune response than a consensus vaccine.  This increased breadth 
is linked to increases in the level of protection against heterologous viral challenges.  Further 
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development of the polyvalent vaccine addressing the issues raised above will likely improve the 
immunogenicity and protective effect of this vaccine  
This work is the starting point for developing a broadly reactive HIV/AIDS vaccine.  
These results indicate that the best strategy to carry forward is a polyvalent vaccine.  While the 
best strategy was identified an optimal vaccine delivery regimen was not.  Future work should be 
focused on optimizing the current PolyB Env VLP vaccine.  All future studies will need to be 
completed in NHPs for the optimization of this vaccine.  The findings within Aim1 and Aim2 
highlight the differences in the immune responses generated in rodent systems as compared to 
non-human primates.  As this vaccine is eventually intended for human use, its optimization 
should be completed in the non-human primate model as this better mimics the human immune 
response.  First increasing the doses of antigen delivered either through the use of viral vectors or 
increased purification should be researched.  Next increased immune responses to envelope 
should be investigated using gp140 trimers to prime the anti-Env immune response.  Lastly other 
adjuvants should be used to facilitate the induction of stronger immune responses.  After optimal 
anti-Env immune responses are generated, additional challenge studies should be initiated using 
SHIVSF162p4 as well as more pathogenic challenge viruses.  Additionally cross-clade challenges 
should be completed to determine the level of cross-clade protection.   It will be important to 
determine if multiple clade specific or multi-clade vaccines will be needed to protect against 
different clades. 
This dissertation has shown that a Polyvalent clade B Env VLP-based vaccine is best able 
to generate a broadly reactive immune responses.  These immune responses are able to reduce 
the rate of infection against a heterologous viral challenge.  This work is the beginning in the 
development of a broadly reactive HIV-1 vaccine.  Further work is needed to optimize the 
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immune responses generated by this vaccine to better strengthen the immune responses 
generated.  It is likely based on the data presented above that strengthening of the immune 
responses will lead to a greater degree of protection.   
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7.0  APPENDIX 
Shown below is the data from a pilot NHP study which was conducted at the University of 
Pittsburgh to ensure that the VLPs were immunogenic.  All NHPs received four vaccination on 
four week intervals.  All vaccines were given at a dose of 250 µg of VLP with 125 µg CpG 
adjuvant in 500 µl sterile saline delivered via the intramuscular route.   
Table 10 Pitt Virus-like Particle Vaccines 
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Figure 27 Pre-challenge antibody responses. 
Serum samples were collected 2 weeks following the final vaccination.  Serial dilutions were 
tested against either 50 ng of homologous VLP(A) or 50 ng of SF162 gp120(B).  Results are 
shown as individual responses per group along with the average response.  Statistics were 
completed using student’s t-test. *p-value<.05 
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Figure 28 Pre-challenge Cellular Immune Responses. 
Cellular immune responses were measured for PBMCs isolated two weeks following the final 
vaccination.  Cells were tested against various peptide pools representing the different regions of 
Env (SF162 Env peptide set, NIH AIDS RRRP) as well as HIV Gag (NIH AIDS RRRP).  
Results are shown as the average responses per group (N=4).   
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Figure 29 Pitt IR SHIV-SSF162p4 Challenge. 
All groups were challenged intrarectally with 640 TCID50 of SHIVSF162p4 virus eight weeks 
following the final vaccination.  (A) Viral loads are shown as the average +/- the SD for each 
group (Naïve N=6, ConB N=4, PolyB N=4, Gag N=2).  (B) The area under-the-curve for each 
individual viral load was taken to determine the viral burden over the course of infection. (C) 
CD4
+
 lymphocyte counts were observed throughout the infection course.         
 
 137 
 
Figure 30 Post-Challenge Anti-Env antibody responses. 
Antibody responses to SF162 Env were tested by ELISA (A) and Neutralization assay (B) 
throughout the post-challenge observation period.  Results are shown as the average response 
from each infected NHP by group.  Non-infected NHPs were not included as no changes in their 
immune responses were observed post-challenge.   
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Figure 31 Post-challenge Cellular Responses. 
Cellular immune responses were measured for PBMCs isolated at day 84 post-infection.  Cells 
were tested against various peptide pools representing the different regions of Env (SF162 Env 
peptide set, NIH AIDS RRRP) as well as SIV Gag (NIH AIDS RRRP).  Results are shown as the 
average response from each infected NHP by group. 
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